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Abstract 
	  
The purpose of the work presented in this dissertation was to investigate the correlation 
between the particle size of crystalline active pharmaceutical ingredients (APIs) and their solid-
state NMR (SSNMR) proton spin-lattice relaxation times (1H T1) using model compounds. 
Dicumarol and salicylic acid were selected as model compounds for this study.  
Crystalline samples of the model compounds containing particles with sizes ranging from 
1 µm- 800 µm were prepared by sieving, spray-drying, and anti-solvent precipitation. The 
physical state and the particle size of the materials prepared were characterized. A model that 
describes the correlation observed between the 1H T1 time of the dicumarol and the salicylic acid 
materials and their particle size was proposed. The model was based on the assumption that spin 
diffusion is the main spin-lattice relaxation mechanism.  
The way that SSNMR relaxation time measurements could be used to characterize the 
polydispersity of crystalline powders using physical mixtures of dicumarol was also investigated. 
A short investigation of the effect of different compaction forces on the homogeneity of 
formulated tablets of salicylic acid was also conducted. Different 1H T1 times were obtained for 
salicylic acid at all compaction forces, and heavier compaction forces lead to a larger decrease in 
1H T1 time.  
Finally, the effect of grinding on the chemical stability of a crystalline API gabapentin 
was investigated. Changes in 1H T1 times of ground crystalline gabapentin Form II were 
correlated with the chemical stability of the material: samples with shorter 1H T1 times were the 
least chemical stable. The physical meaning for the reduction in 1H T1 time observed was 
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believed to be both the presence of crystal defects and the decrease in particle size of the 
material.  
This research provided evidence that SSNMR can be used to characterize bulk properties 
as well as molecular level characteristics of pharmaceutical solids. This could improve the 
characterization of formulated drug products during drug development. 
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1.1 Introduction 
The overall objective of the work presented in this dissertation is to characterize the 
particle size of crystalline solids in pure active pharmaceutical ingredients (API) powders and in 
formulated drug products using solid-state NMR spectroscopy (SSNMR) relaxation time 
measurements, and subsequently correlate the measurements to functional pharmaceutical 
properties such as dissolution rate and drug stability.  
The particle size of crystalline pharmaceuticals impacts a number of important 
pharmaceutical properties such as the dissolution rate, the manufacturability of the powder and 
the dose uniformity in the final formulated drug product 1-5. However, it is extremely difficult to 
measure particle size of drug crystallites after they have been formulated, and in particular in a 
tablet. Solid-state NMR spectroscopy has emerged as a powerful technique for the 
characterization of solid pharmaceuticals. One of the main advantages of that technique is that it 
can be used to characterize APIs within a formulation. SSNMR is generally thought of as a 
molecular level technique; however, previous work performed in our laboratory suggests that it 
could be used to characterize bulk properties of solid pharmaceuticals such as particle size. 
SSNMR will be discussed in more detail in the following chapter; in this introduction 
chapter, characteristics of pharmaceutical solids in general, and crystalline solids in particular, 
are presented. The relevance of the particle size and morphology of solid pharmaceuticals to 
drug development is also discussed, as well as the impact of processes used during development 
on these properties. Finally, the motivation for the work presented in this dissertation is 
presented in more detail and the remainder of the dissertation is outlined.  
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1.2 Pharmaceutical Solids  
Small molecule oral solid-state formulations represent the majority of drug products 
currently on the market. They offer significant advantages over parenteral formulations like 
injectable formulations, such as higher stability, cheaper manufacturing cost, and higher patient 
compliance. Solid drug products are composed of an active pharmaceutical ingredient (API) and 
excipients, which are the pharmaceutically inactive materials that serve as bulking agents, 
stabilizers or lubricants. Solid APIs can exist in either the crystalline or amorphous state. The 
most stable crystalline form of an API is typically preferred when developing a drug candidate 
because it will not convert into other forms, and is less likely to have chemical stability problems 
compared to less stable forms such as the amorphous form. Nonetheless, crystalline 
pharmaceutical solids can also present challenges such as low bioavailability or poor 
manufacturability, and even physical and chemical instability during the drug development 
process. A number of these issues arise from the polymorphism of the crystalline solids. Others 
are due to the size and the morphology of the particles in the solid powder. The research 
presented in this dissertation focuses extensively on crystalline materials, and in particular on the 
particle size of crystalline solid pharmaceuticals. For this reason, the properties of crystalline 
materials will be described in the following sections.   
1.3 Crystalline solids 
A compound that is crystalline has its molecules ordered in a three-dimensional repeating 
unit that forms a lattice. The smallest repeating unit, called a unit cell, is composed of one or 
more molecules that have a fixed conformation and/or arrangement in the unit cell. If the unit 
cell repeats infinitely without interruption, a single crystal results. Crystals may also be 
composed of aggregates of smaller single crystals. Crystals may contain some imperfections that 
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occur as a result of processing or during growth. These imperfections are commonly referred to 
as crystal defects. 
Crystals are often grown from supersaturated solutions, which are solutions where the 
compound is present at a higher concentration than its equilibrium solubility. Crystal growth 
begins with nucleation, which occurs when a critical number of molecules come together to 
create a small crystallite that is thermodynamically stable. Nucleation can be triggered by a 
number of factors, including the addition of a seed crystal to the supersaturated solution. Crystal 
formation can result from evaporation of the solvent from a solution, the addition of an anti-
solvent, or from a change in pH of the solution. All these actions cause the metastable state of the 
supersaturated solution to be disturbed, resulting in crystals forming from the solution. The 
crystallization conditions can be altered in order to obtain crystals of different sizes.  
1.3.1 Relevance of particle size and morphology 
 A polycrystalline material is a collection of crystallites that forms a powdery material, 
and the properties associated with that powder are highly dependent on the size as well as on the 
shape, or morphology, of its particles. Some of the pharmaceutically relevant properties of solid 
powder that are affected by particle size and morphology include the dissolution rate and the 
manufacturability of the powder 6-8. In fact, the guidelines issued by the International Conference 
on Harmonization (ICH) list particle size as one of the physical properties that influence the 
manufacturability and the performance of solid drug products. The ICH also issued an 
acceptance criteria flow chart for the particle size distribution of solid pharmaceuticals (Figure 
1.1). The way that particle size affects the dissolution rate of solids can often be described by the 
Noyes-Whitney equation.  
!"
!"
= !"(!!!!)
!
  (1.1) 
 
 5 
Setting acceptance criteria for drug substance particle size distribution 
 
 
 
 
 
 
Figure 1.1 ICH guideline Q6A
Is the drug product a solid 
dosage form or liquid 
containing undissolved drug 
substance? 
No drug substance particle 
size acceptance criterion 
required for solution dosage 
forms 
1. Is the particle size critical to dissolution, 
solubility, or bioavailability? 
2. Is the particle size critical to drug product 
processability? 
3. Is the particle size critical to drug product 
stability? 
4. Is the particle size critical to drug product 
content uniformity? 
5. Is particle size critical for maintaining 
product appearance? 
Set acceptance criterion 
No acceptance criterion 
required 
NO 
YES 
If NO to all 
If YES to any 
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where dS/dt is the dissolution rate, D is the diffusion coefficient, A is the surface area, Cs is the 
concentration of the solid in the diffusion layer h immediately surrounding the drug particle, and 
C is the concentration of the solid in the bulk medium. A decrease in particles size leads to an 
increase in surface area of the particles, which in turn leads to a faster dissolution rate of the 
solid material.  In theory, an increase in surface area by a factor of 10 leads to an increase in 
dissolution rate by the same amount, which in turn may improve the bioavailability of the 
pharmaceutical solid.  This ability of smaller size particles to improve the bioavailability of a 
solid drug has triggered a large volume of investigations on ways to produce nanoparticles of 
poorly soluble APIs, such as BCS Class II and Class IV compounds 9-12. Two main approaches 
for decreasing particle size exist, namely the top-down and the bottom-up approaches. While 
ways to generate particles as small as hundreds of nanometers have been developed, the physical 
state characterization of these small size systems poses a challenge. That is because the impact of 
particle size on the response of commonly used characterization techniques such as differential 
scanning calorimetry (DSC) is not yet fully understood 13,14. 
Apart from impacting the bioavailability of the drug product via modulating the 
dissolution rate of the material, the particle size of solid pharmaceuticals can also impact the 
bioavailability of the drug product by dictating the site of drug absorption. This is the case for 
nasal and pulmonary drug delivery systems where the bioavailability of the drug heavily relies 
on the size of the particles in the drug product. Particles ranging from 1-5 µm are the ideal size 
for inhalation and respiratory drug products because their aerodynamic properties dictate that 
they are deposited in the most vascularized area of the lungs and nose, allowing for the greatest 
likelihood of drug absorption 15. On the other hand, the size of the particles of solid drug 
products for oral delivery is dictated by their manufacturability. Particles for oral dosage 
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formulations typically range from 100-200 µm because particles in this size range tend to have 
the best flow properties, which allow for easier manufacturing. Nonetheless, homogeneous 
mixtures of these larger size particles are not easily obtained, and when a variety of particle sizes 
are present, segregation can occur 7. Also, smaller particles (20-50 µm) are preferred for 
chewable and fast-disintegrating oral tablets because of their faster dissolution rate 15. The 
difficulty in obtaining homogeneous mixtures of solid pharmaceuticals can lead to a lack of dose 
uniformity in the final drug product, especially for low dose (< 5mg) drug products 2. The impact 
of particle size on the dose uniformity of the final drug product has been studied, and models that 
attempt to identify the particle size distribution that will provide the highest dose uniformity for a 
given drug have been proposed 1,3,4. However, in certain cases a broad particle size distribution 
of the API may be desired for drug delivery reasons; for example, a mixture of different particle 
sizes could be used to tune the release properties of the drug product 15.  
The particle morphology of a material can also have a significant effect on the drug 
product performance and on the powder manufacturability 16,17. Particles with a spherical 
morphology are typically easier to manufacture because they have better flow properties. 
Conversely needle and rod type particles have more resistance to flow. Particle morphology has 
also been shown to impact the ability to tablet some solid APIs 16. Also, differences in the shape 
of the particles within a solid drug product have been shown to cause non-homogenous mixtures 
7. 
A number of processing steps are used to modify the particle size and the particle 
morphology of crystalline solids in order to improve their manufacturability and/or improve the 
drug performance. These include milling, wet and dry granulation, blending with excipients and 
more. However, some of these processes can cause changes in physical state thus affecting the 
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physical and/or the chemical stability of the drug product. Common manufacturing processes and 
their potential effect on the stability of solid pharmaceuticals are discussed below. 
1.4 Effect of common processing methods on crystalline solids properties 
During manufacturing, solid APIs are often exposed to a variety of temperature and 
humidity conditions, which combined with the stress of the manufacturing processes, can 
potentially cause unwanted physical transformations. For example, a material can convert to 
another solid form such as a different crystalline form, a hydrated or solvated form, or an 
amorphous form. After a brief discussion of polymorphism, the impact of manufacturing on the 
physical state of crystalline solid APIs will be discussed.  
1.4.1 Polymorphism 
Polymorphs of a crystalline material have the same chemical structure but differ in the 
conformation or arrangement of the molecules in the unit cell. The polymorphs of a material may 
vary greatly in their physical properties such as density, melting point, solubility, or 
hygroscopicity. This leads to significant differences in important pharmaceutical properties such 
as dissolution rate and physical and chemical stability. For this reason, polymorph screening, 
characterization, and selection are a vital part of the drug development process. Under a 
particular set of temperature and pressure conditions, one polymorphic form of a compound has 
the lowest Gibbs free energy and is therefore the most thermodynamically stable. That most 
stable form is generally preferred for use in the final drug product. It is possible for another 
polymorphic form to be the most stable form under different conditions; in that case the two 
forms are said to be enantiotropically related. When one form is more stable than another form at 
all temperatures and pressures, the relationship between the two forms is described as 
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monotropic. Figure 1.2 illustrates the difference between monotropic and enantiotropic systems 
using a graph of energy versus temperature.  
1.4.2 Changes in physical state  
Milling is often the first step in the manufacturing of solid pharmaceuticals, and is 
commonly used to improve the powder flowability of solid pharmaceuticals either by reducing 
the size of the particles in order to obtain a more uniform powder, or by changing the 
morphology of particles from needles to more spherical 2. However, milling generates heat and 
causes mechanical stress that can lead to polymorphic conversions. A number of APIs have been 
shown to undergo polymorphic conversions when milled 18,19. Wet-granulation is another 
commonly-used manufacturing process that is employed to impart better flowability and 
compressibility to the material. However, wet-granulation is especially prone to causing 
polymorphic conversions because of the presence of a liquid phase 20,21. The presence of 
excipients during wet granulation can also cause changes in physical state 22. Dry granulation can 
be used as an alternative to wet granulation in order to avoid the use of a solvent, but the 
mechanical stress induced by the process can also cause physical state changes. Finally, the 
compression forces used during tableting of the drug product may be very high and can also lead 
to physical transformations of the solid API 20,23.   
The ability to detect any physical conversions of the API that occurred as a result of 
processing can be a difficult task due to the complexity of solid formulations, and numerous 
analytical techniques often have to be used. Moreover, the mechanical stress induced by some of 
the manufacturing processes discussed above can not only cause polymorphic conversions, they 
can also lead to changes in the chemical stability of the material 24. In cases where particle size 
control of the API is absolutely necessary for effective drug delivery, the particle size must also 
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a.        b. 
 
Figure 1.2 Plot of the free energy versus temperature showing how a monotropic and an 
enantiotropic polymorphic system differ from each other.  
a. monotropic polymorphic system; b. enantiotropic polymorphic system. In the enantiotropic 
system the relative stabilities of the polymorphs are reversed past a transition point.  
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be well characterized. The characterization of the APIs in the presence of the excipients in a 
formulation is only possible using a handful of analytical techniques, one of which is solid-state 
NMR. 
1.5 Motivation for this work 
1.5.1 Advantages of solid-state NMR for the characterization of solid pharmaceuticals 
Solid-state NMR (SSNMR) is an superbly powerful tool for the characterization of solid 
pharmaceuticals, and studies in the Munson laboratory and other laboratories have demonstrated 
the applicability of SSNMR to the physical state characterization of solid APIs both alone and in 
the presence of excipients within formulations 25-27. Solid-State NMR is one of the few analytical 
techniques available for the characterization of complex solid mixtures containing the API and 
the excipients. To the best of our knowledge, no study has investigated the ability of SSNMR to 
characterize other physical properties of crystalline solid pharmaceuticals such as particle size or 
particle morphology. Part of the reason is that SSNMR is typically thought of as a molecular 
level technique.  
1.5.2 Previous work 
Results of previous study performed in the Munson laboratory have suggested that 
SSNMR proton spin-lattice relaxation (1H T1) times are sensitive to changes in crystalline solids 
brought about by common manufacturing processes such as milling. One such study was 
performed by Lubach and coworkers with lactose monohydrate as a model compound 28. In their 
study, Lubach and coworkers cryoground crystalline α-lactose for different lengths of times and 
obtained 1H T1 times and 13C SSNMR spectra of all the samples. They found that at longer 
grinding times, crystalline lactose converted to amorphous lactose. This was obvious by the 
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significant line broadening observed in the SSNMR spectra. Lactose ground for 2 min remained 
crystalline, yet its 1H T1 time was an order of magnitude shorter than that of the unground 
material. That reduction in 1H T1 magnitude was believed to be due to the creation of crystal 
defects. However, particle size reduction also happened during milling, and the influence of 
particle size on the decrease in 1H T1 time observed was not investigated. It is this correlation that 
will be investigated in this dissertation. 
1.6 Overview of the dissertation 
Chapter 2 contains a description of the techniques, with an emphasis on solid-state NMR 
relaxation time measurements. Chapter 3 introduces the theory behind the correlation between 
particle size and 1H T1 times. Chapter 4 presents the selection of the model compounds used for 
the remainder of the dissertation and the preparation and physical state characterization of the 
different samples. Chapter 5 focuses on the correlation between the size of the particles in the 
samples prepared and the 1H T1 relaxation times of the materials, and presents a proposed model 
between particle size and 1H T1. Chapter 6 shows how the polydispersity of a material can be 
characterized by its 1H T1 relaxation, including applications to the study of formulated tablets and 
a correlation to dissolution rates. In Chapter 7, the correlation between 1H T1 times and chemical 
stability of ground samples of a model system, gabapentin, is presented. Finally, Chapter 8 will 
discuss future possible directions or extensions for this research. 
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Physical State Characterization and Particle Size Measurements of 
Pharmaceutical Solids 
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2.1 Introduction 
In this chapter techniques that can be used to characterize the particle size and the 
physical state of crystalline solid pharmaceuticals, including laser diffraction, microscopy and 
solid-state NMR (SSNMR) are discussed. In the previous chapter some of the basic properties of 
crystalline solids and their impact on pharmaceutical properties were presented. In particular, the 
central role that the particle size of pharmaceutical solids plays on their manufacturability and 
the way that it can impact the drug product uniformity and the bioavailability of the drug product 
were discussed. The potential for commonly used manufacturing processes to modify the size 
and the morphology of solids, to cause changes in the physical state of the API such as 
polymorphic conversions, or to result in crystalline to amorphous conversions was also 
mentioned 1-3. These changes could lead to poorer bioavailability and decreases in chemical 
stability. As a result, it is important for the particle size and the physical state of the pure solid 
API and the final formulated drug product to be well characterized.  
 
2.2 Particle size measurement techniques  
There are several methods available to measure particle size, and the choice of method used 
often depends on the expected size of the particles in the sample analyzed. In an excellent review 
article, Shekunov and coworkers discussed the particle sizing techniques that are applicable to 
pharmaceuticals as well as the principles of operation and shortcomings of each 4. Laser 
diffraction and microscopy are two of the most commonly used techniques. The following is a 
short description of their principles of operation and the particle size range that they can be used 
to measure. The limitations of each method will also be discussed.  
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2.2.1 Laser diffraction techniques 
Laser diffraction operates on the principle that particles that are suspended in a liquid 
produce a diffraction pattern as they pass through a laser beam. This pattern is dependent on the 
size of the particles. Laser diffraction is used to measure particles ranging from 0.5 to 1000 µm 
in size 4. Laser diffraction measurements are volume-based: the angle and the intensity of the 
scattered light are function of the volume of the particles. Equations relating scattering to volume 
are then used to calculate the diameter of the particles from the volume measurements and to 
provide a particle size distribution 4. The results are often represented in terms of percentile 
values, where the d10, d50, and d90 values are the numbers below which 10, 50, and 90% of the 
volume of the sample lies. Laser diffraction measurements require the solid to be suspended in 
solution often with a surfactant added. For some materials, that step may cause the particles to 
agglomerate, and therefore sonication is often used to break down these agglomerates and any 
other agglomerate that may already be present in the sample. Whether a sample is sonicated 
before measurements and for how long can affect the particle size results obtained, as both 
aggregates and actual particles can be broken down during sonication. Figure 2.1 illustrates the 
impact of sonication on laser diffraction results.  In Figure 2.1, the laser diffraction data obtained 
for a sample of dicumarol that was suspended in water with and without prior sonication are 
shown; the sample that was sonicated contains smaller particles than the unsonicated material. 
Another parameter that can affect the data obtained by laser diffraction is the morphology of the 
particles in the solid 4. The equations used to obtain the diameter of the particles assume that they 
have a spherical morphology, which is not always the case. 
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Figure 2.1 Laser diffraction results for a sample of as received dicumarol with or without prior 
sonication. A small amount of powder was suspended in water and for one sample the 
suspension was sonicated prior to performing the measurements. This figure illustrates the 
potential impact of sonication on the particle size results obtained by laser diffraction.  
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This is important because spherical particles can be described with only one dimension, their 
diameter, whereas needle or rod-shaped particles need two dimensions to be described. Laser 
diffraction is a useful technique to compare the size of particles from one batch to another, and it 
has the advantage of being quick and of requiring less than 1 g of sample for analysis; however, 
it should be combined with other size techniques such as microscopy in order to obtain a truly 
accurate image of the material being analyzed.  
2.2.2 Microscopy 
Microscopy is frequently used to assess the size of particles in solid materials, especially 
as an orthogonal technique to laser diffraction, and it is the only method where the individual 
particles can be observed and by which the morphology of the particles can be determined. 
Optical microscopes can be used to study the surface of objects or individual crystals depending 
on if they use reflected or transmitted light. Optical microscopy only requires that the sample be 
dispersed over a surface such as microscope slide. Particles that are too small to be imaged by 
optical microscopy (less than 0.5 µm) can be observed by scanning electron microscopy (SEM). 
SEM is also a more powerful tool to investigate the surface of a material. Electron microscopy 
uses focused electron beams instead of light to allow imaging of the material. The size range of 
particles that can be observed by SEM is 0.01-150 µm. SEM requires that the sample be coated 
with a conducting metal such as gold.  
Atomic force microscopy (AFM) is another form of microscopy that has also been used 
to characterize the size and shape of particles. During AFM analyses, a probe is made to travel 
over the surface of the sample to obtain a topological map. The images obtained are similar to 
the ones obtained by SEM, with a resolution down to the nanometer range. AFM is a relatively 
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slow method and the sample preparation may be very involved. However, unlike SEM, it does 
not require coating of the material with a conductive metal. 
2.2.2 Other size measurement techniques 
Other particle sizing techniques were briefly used in the course of the investigation 
presented in this dissertation. They include dynamic light scattering (DLS) and Coulter Counter. 
DLS involves the measurement of fluctuation in laser intensity occurring as a result of scattering 
by particles moving in a Brownian motion in solution. The sensitivity of DLS instruments should 
be validated by size standards. The speed of the experiment and the fact that no calibration is 
required are some of the advantages of this technique. However, the presence of particles larger 
than 3 µm may skew the measurements5. The Coulter Counter is another popular volume-based 
particle sizing instrument. It measures the change in electrical impedance as particles pass 
between two electrodes. This change is correlated with the volume of the particle and is then 
converted to a particle size distribution as more particles pass through. It can be used for a 
similar range of sizes as laser diffraction. The analysis is fast and the results are considered 
highly reproducible. However, it can be difficult to characterize highly water-soluble materials 
using this method because the particles have to be suspended in a weak aqueous electrolyte 
where highly soluble compounds could dissolve.  
Table 2.1 summarizes existing particle sizing methods and includes the range of sizes that 
can be measured by each technique. It is important to note that the size measurements obtained 
are very method dependent; therefore, it is crucial to combine two or more analysis methods in 
order to improve the accuracy of the results 5.  
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Table 2.1 Summary of commonly used particle size measurement techniques 
 
 
 
 
 
 
 
 
 
 
 
 
Technique Principle Measuring range (µm) 
Optical microscopy Direct imaging 
3-150 
Scanning Electron 
Microscopy (SEM) Direct imaging 
0.01-150 
Laser diffraction Low angle diffraction rings measurement 
0.5-1000 
Dynamic Light Scattering 
(DLS) 
Measurement of light intensity 
correlations from particles in Brownian 
motion 
0.003-3 
Coulter Counter Change in impedance 
0.6-1200 
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2.3 Physical form characterization techniques 
 As mentioned in the introduction, changes in the physical state of the solid API can occur 
when its particle size and particle morphology are modified during manufacturing. For this 
reason, it is important to characterize the physical state of the drug product.  A number of 
physical-state characterization techniques are available, and some of the most widely used 
methods include thermal methods, imaging techniques, X-Ray diffraction, and spectroscopic 
techniques such as Raman, infrared and solid-state NMR spectroscopy (SSNMR). A 
combination of microscopy, X-Ray diffraction, thermal methods and SSNMR was used to 
characterize the physical state of the materials in most of the work presented in this dissertation. 
In the next section we will describe the type of information that can be provided by each of those 
techniques.  
2.3.1 Thermal methods 
Differential scanning calorimetry (DSC) is one of the most commonly used thermal methods 
for the physical-state characterization of solids. It involves measuring the difference in heat flow 
between the sample and a reference as both are heated.  Phase transition events, such as melting 
and recrystallization, that occur as a result of the change in temperature are recorded. Melting 
and recrystallization events appear in a DSC thermogram as endotherms and exotherms 
respectively. The melting point of a material can be obtained from the melting endotherm and 
can be used to distinguish between polymorphs of a material that have different melting points. 
DSC can also be used to detect the presence of amorphous material. It is the method of choice 
for measuring the glass transition temperature (Tg) of amorphous materials, which represents a 
change in heat capacity in the material as it transitions from the glassy to the rubbery state. 
Figure 2.2 shows examples of thermal events that can be observed in a DSC thermogram. 
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A disadvantage of DSC is that it is difficult to characterize complex mixtures like 
formulations containing both an API and excipients using that technique because of the possible 
overlap of thermal events. In this dissertation, DSC was used as a complementary technique to 
solid-state NMR to check for the presence of amorphous material that might have been generated 
as a result of different pharmaceutical processes such as freeze-drying and spray-drying. More 
details on the operating principles of DSC and its numerous applications to the characterization 
of pharmaceutical of solids and other pharmaceutical systems have been outlined in a review by 
Clas and coworkers 6.  
2.3.2 Imaging techniques 
Polarized light microscopy is often used to distinguish between crystalline and amorphous 
material. In a birefringent microscope, the light passes through a set of polarizers. The angle of 
polarization of the light changes as it passes through a crystal, resulting in different colors in the 
image. Amorphous material appears the same color as the background. The angle at which the 
second polarizer is placed with respect to the first one determines the color of the crystal 
observed through the microscope lenses. Single crystals appear yellow or blue under polarized 
light microscopy, while aggregates of crystals appear green. When the stage of the microscope is 
rotated by 90º, the coloring of single crystals switches. Figure 2.3 shows polarized light 
microscopy images of a crystal of gabapentin, before and after rotating the stage of the 
microscope by 90 º. Polarized light microscopy is a rapid way to assess the crystallinity of a solid 
material; however, only a small amount of sample is imaged, and it may not be an accurate 
representation of the material overall. 
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Figure 2.2. DSC thermogram of amorphous acetaminophen. This DSC contains some of the 
typical thermal events that can be observed by DSC. a. a glass transition; b. an endothermic peak 
indicating recrystallization and c. an endothermic peak indicating melting of the material. 
The thermogram was obtained using a TA Instruments DSC instrument. 
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a.       b. 
 
Figure 2.3. Polarized light microscopy images of crystalline gabapentin Form II; b. was taken 
after rotating the stage of the microscope by 90º. The crystals appear as yellow or blue, 
indicating that they are single crystals. Rotating the stage of the microscope by 90º causes the 
colors to inverse. 
The images were obtained on an Olympus microscope. 
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2.3.3 X-ray diffraction 
X-ray diffraction techniques are based on the principle of X-rays being scattered by the 
atoms in a molecule to produce unique diffraction patterns. Single crystal X-ray diffraction is 
used for crystal structure elucidation, which is helpful when trying to understand how the 
molecules are packed in a given polymorph, or how spatially close reactive functional groups are 
to each other. When single crystals are not available, powder X-ray diffraction (PXRD) can be 
used to distinguish between polymorphs as well as between crystalline and amorphous materials 
based on the peak positions and breadth 7-9. The PXRD patterns of crystalline peaks are 
characterized by sharp peaks, whereas a shapeless halo is characteristic of amorphous materials 
10. This difference exists because crystalline materials are composed of a highly ordered lattice of 
molecules that scatters the X-ray constructively at defined angles; conversely, amorphous 
material lack that order and do not produce a pattern with sharp peaks, but a halo instead. One of 
the advantages of PXRD is the small amount of material that is required for analysis. However, 
artifacts that can impact the intensity of the peaks in the diffraction pattern can arise due to the 
preferred orientation of crystals in a powder. This is especially true for particles with a non-
spherical morphology 11,12. Furthermore, PXRD patterns of formulations can be difficult to 
decipher because of the peak overlap of the different components. 
2.3.4 Solid-state NMR spectroscopy 
Solid-state nuclear magnetic resonance spectroscopy (SSNMR) is a non-destructive, 
selective and quantitative technique that is highly useful for analyzing solid pharmaceuticals 13. 
The chemical shifts and linewidths of the peaks in an NMR spectrum can provide a wealth of 
information on a material, including information on its chemical structure, its composition, 
whether it is pure or a mixture, and its physical state, e.g. crystalline or amorphous. Studies have 
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also shown that the morphology of the particles in a crystalline sample could possibly be related 
back to the linewidth of the peaks in its SSNMR spectrum 14. SSNMR relaxation times provide 
mobility information, and also have been related to chemical stability 15. Because solid-state 
NMR is the main solid-state characterization technique used in the work presented in this 
dissertation, it is discussed in greater details in the following sections.  
2.4 Fundamentals of Nuclear Magnetic Resonance Spectroscopy 
Nuclei that have an angular momentum, and therefore a magnetic moment, are NMR 
active. The spin quantum number I describes the angular momentum of the spinning charge. We 
will only be concerned with nuclei with I=1/2, such as 1H and 13C, in this work because they are 
the most pharmaceutically relevant. In the presence of an external magnetic field B0, these nuclei 
begin to precess about an axis that is at an angle of 54.7º with respect to the magnetic field B0. 
The rate of precession is proportional to both the strength of B0 and a constant specific to each 
nucleus called the magnetogyric ratio γ. The orientation of the nuclear spins is random in the 
absence of a magnetic field, but in the presence of a strong magnetic field (such as in an NMR 
spectrometer), nuclear spins with I=1/2 can align either parallel (α state) or anti parallel (β state) 
to the magnetic field B0 (Figure 2.4). Because one of the states has a lower energy level, it 
contains a small population excess of nuclei. This population excess can be calculated using the 
Boltzmann equation: 
!!""#$
!!"#$%
=   !!!!/!"     (2.1) 
where Nupper and Nlower are the populations of nuclei in the higher and lower energy state 
respectively; k is the Boltzmann constant, T is the absolute temperature, and ΔE is the difference 
in energy between the two states. ΔE can be calculated using the following equation: 
Δ! =    !!!!
!!
= ℎ!!    (2.2) 
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Figure 2.4. Energy diagram for the two energy levels, denoted α and β, that can be assumed by 
spin ½ nuclei 
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where γ is the magnetogyric ratio of the nucleus, h is the Planck’s constant, and ν0 is the 
frequency of the nucleus. When a radiofrequency (RF) pulse equal to the difference in energy 
(ΔE) between the two states is applied in the appropriate direction to the material, the nuclei 
absorb energy that causes them to transition from one energy state to the other. These nuclei are 
oriented with respect to one another, and the net magnetic moment of the precessing nuclei 
creates an alternating current signal in the NMR detection coil at a frequency of the precessing 
nuclei. This signal, called a free induction decay (FID), is observed during an NMR experiment. 
The FID is recorded in the time domain, and it is converted to the frequency domain (Hz/MHz or 
ppm) by a Fourier transform. The resulting spectrum contains peaks whose chemical shifts, or 
positions, and linewidths, or breadth, can provide us with a wealth of information about the 
sample. The process through which the system returns to equilibrium after the pulse is termed 
relaxation. Different relaxation processes exist, including spin-lattice relaxation and spin-spin 
relaxation.  In spin-lattice relaxation, the nuclei transfer the excess magnetization acquired 
during the pulse in order to return to their equilibrium state. Relaxation will be discussed in more 
detail later in this chapter. 
2.5 Solid-state NMR spectroscopy 
Before we discuss how solid-state NMR chemical shifts, linewidths and relaxation 
measurements are used to characterize solid pharmaceuticals, it is useful to point out how solid-
state and solution-state NMR differ from each other. This will be helpful in order to understand 
why solid-state NMR is less routinely used than its solution-state counterpart, and why it is a 
powerful tool to the study of solid pharmaceuticals.  
In the solution state, the molecules are rapidly moving and tumbling around, causing the 
several interactions among the nuclei in a molecule to average to either zero or an isotropic 
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value. Conversely, the molecules in the solid state are held rigidly in place; therefore, this 
averaging does not occur. This causes the linewidths of the peaks in the SSNMR spectrum to be 
significantly broader than the ones present in a solution-state NMR spectrum. One interaction 
that causes the lines to be broad is dipolar coupling between either 1H-1H or 13C-1H. In section 
2.5.1, we describe how high power decoupling is used to eliminate this cause of line broadening.  
Another cause of line broadening in the solid state is the chemical shift anisotropy (CSA) of the 
materials, which means that all the orientations assumed by the nuclei with respect to the 
magnetic field B0 contribute to the chemical shift of the material observed in an NMR spectrum. 
While the tumbling of the molecules in solution averages all the angular-dependent orientations, 
this does not occur in the solid state, and the distribution of all the orientations that can be 
assumed by the nuclei results in a broad spectrum called a powder pattern. Figure 2.5 shows the 
difference between the solution and the solid-state NMR spectra of 3-methylglutaric acid. The 
use of a technique known as magic-angle spinning in solid-state NMR, described in section 
2.5.3, eliminates the orientations that are angular dependent resulting in narrower peak 
linewidths. Finally, NMR active nuclei that have a low natural abundance, like 13C, often have 
very long spin-lattice relaxation times. The consequence of this is longer NMR experiments. 
Transfer of magnetization from abundant nuclei such as protons to these low abundance nuclei 
by a process called cross polarization can be used to alleviate that issue and enhance the 
sensitivity, which is a factor of 4 for 1H-13C. Cross polarization will be discussed in section 2.5.2. 
2.5.1 High power decoupling 
Dipolar coupling is the through-space interaction between the dipole moment of one 
nuclear spin and the dipole moment of another nucleus. The strength of the dipolar coupling  
 
	  
 33 
 
 
 
 
 
 
 
 
  
 
 
Figure 2.5 Solid-state and solution-state NMR spectra of 3-methyl glutaric acid (MGA). These 
specra denote the differences in linewidths obtained in solution state and solid state NMR. The 
solid-state spectrum is very broad and is denoted a powder pattern. The peaks in the solution 
NMR spectrum are very sharp by contrast. 
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decreases very rapidly with the cube of the distance between the two coupled nuclei according to 
the following equation: 
!!" =
!!ℏ!!!!
!!!!"
!   (2.3) 
where DIS is the strength of the dipolar coupling between two spins I and S, µ0 is the vacuum 
permeability constant, γI and γS are the magnetogyric ratio of spins I  and S, respectively and rIS 
is the distance between the two spins. Both homonuclear and heteronuclear interactions can 
exist; however, with dilute nuclei such as 13C (1.1% abundant), homonuclear interactions are 
essentially negligible because there is only a small probability for two 13C nuclei to be in close 
proximity to each other. In contrast, 13C-1H and 1H-1H interactions are very prevalent because of 
the 100% natural abundance of protons. Equation 2.3 also indicates that the strength of the 
coupling is proportional to the magnetogyric ratio of the nucleus. The magnetogyric ratio of 
protons is about four times as large (26.8 x 10-7 !"# ∙ !!! ∙ !!!) compared to that of 13C (6.7 10-7 
!"# ∙ !!! ∙ !!!), which means that dipolar couplings involving protons are very strong. We will 
discuss in the next chapter how the strong 1H-1H dipolar coupling can be used for measuring 
distances by NMR. This strong dipolar coupling causes line broadening of the peaks in a 
SSNMR spectrum; high power decoupling fields on the order of 60 kHz applied at the proton 
resonance frequency are used to eliminate the 13C-1H interactions, resulting in narrower peaks.  
2.5.2 Cross polarization 
The use of cross-polarization allows us to take advantage of the high natural abundance 
of nuclei such as 1H to improve the sensitivity of dilute nuclei such as 13C through a 
magnetization transfer that takes place through dipolar coupling interactions between the two 
nuclei. In practice, cross-polarization is achieved by applying a 90º strong radiofrequency (RF) 
pulse that rotates the proton magnetization into the x-y plane.  These nuclei are then held in that 
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place, or spin-locked, for a time period t. During that time a strong pulse is applied to the 13C 
spins, the carbon field is then switched off, and the carbon FID is recorded. The magnitude of the 
fields applied to the 1H and 13C are chosen to satisfy the Hartmann-Hahn conditions 16:  
! !! B !! = ! !!" B !!"    (2.4) 
where ! !!  and ! !!"  are the magnetogyric ratios of 
1H and 13C respectively, and B is the strength 
of the applied frequency. When Hartmann-Hahn conditions are met, the two nuclei precess at the 
same rate thus allowing for efficient polarization transfer from the 1H to the 13C nuclei. In 
addition, Hartmann-Hahn cross-polarization results in shorter acquisition times for 13C spectra. 
This is because under these conditions the relaxation rate of the material is dictated by the proton 
spin-lattice relaxation, which takes place significantly faster than 13C spin-lattice relaxation. A 
gain in sensitivity of approximately four-fold per scan is also achieved. 
2.5.3 Magic angle spinning  
The observed chemical shift of a nucleus in a SSNMR spectrum can be defined by the 
equation:   
σobs = σiso + σaniso (3 cos2 θ – 1)     (2.5) 
where σobs is the observed chemical shift, σiso is the isotropic chemical shift and σaniso is the 
anisotropic chemical shift. The sum of these contributions, which represents the orientations that 
can be assumed by the nucleus with respect to the magnetic field B0, results in a shape referred to 
as a powder pattern, which may be 200 ppm wide (Figure 2.5). The anisotropic component has 
an angular dependence and can be eliminated through the use of magic-angle spinning (MAS), 
leaving the isotropic chemical shift as the only contributor.  During magic-angle spinning, the 
sample is spun at an angle equal to 54.7 º, known as the magic angle 17,18. At that angle, the 
contribution of the anisotropic component to the observed chemical shift is zero. Typical 
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spinning speeds range from 3000 kHz to 10,000 kHz. MAS eliminates the main anisotropic 
component, however a residual intensity remains in the form of spinning side bands. The 
spinning side bands appear on either side of a peak at a distance equivalent to the spinning speed. 
They can be removed with the use of a pulse sequence called TOtal Suppression of Spinning 
sidebands (TOSS) 19. Spinning the sample at a speed greater than the width of the powder pattern 
can also eliminate the spinning sidebands. A combination of the techniques described above 
allows us to obtain high-quality SSNMR spectra of solid pharmaceuticals. The effect of each 
technique is illustrated in Figure 2.6. 
2.6 Characterization of pharmaceutical solids by solid-state NMR 
 Solid-state NMR is recognized as a very powerful tool for the study of pharmaceuticals, 
and many reports of applications of SSNMR to pharmaceuticals can be found in the literature 
13,20-24. By monitoring a number of NMR parameters such as the chemical shifts of the peak in 
the spectrum, the linewidth of the peaks, and the relaxation rate of the material, a wealth of 
information on the material can be obtained. This includes information on its physical state, the 
existence of chemical interactions, and the amount of mobility of the sample. In the next section 
the information obtained from SSNMR chemical shifts, linewidths and relaxation times is 
summarized. 
2.6.1 Chemical shifts 
The chemical shifts of the peaks in a SSNMR spectrum are dependent on the electronic 
environment experienced by the nuclei. Functional groups can generally be assigned based on 
the position of their peaks in a SSNMR spectrum. In a 13C SSNMR spectrum, aliphatic carbons 
usually appear between 10 and 40 ppm, aromatic carbons are typically found between 100 and 
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Figure 2.6 13C SSNMR spectra of 3-methyl glutaric acid illustrating the impact of the use of 
advanced techniques: magic angle spinning, 1H decoupling and TOSS on the quality of the 
spectrum. The asterisks (*) in the (b) indicate spinning sidebands. The use of TOSS removes 
those spinning sidebands (c) 
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160 ppm, and peaks from carbonyl and carboxylic acid groups are generally between 160 and 
180 ppm. However, unlike the solution state, these values only represent estimates and can vary 
dramatically based on the spatial arrangement of the molecules and the proximity of 
electronegative groups. 
The polymorphs of a given solid have different SSNMR spectra because they differ in the 
conformation and/or packing arrangement of their molecules. Differences in the chemical shifts 
of the peaks can be used to identify the different polymorphs. Figure 2.7 shows the aliphatic 
region of the 13C SSNMR spectra of Form II and Form III of gabapentin. Because of the 
significant difference in the chemical shift of the nitrogen-split peak between Form II and Form 
III, that peak is the most useful for form identification; its chemical shift is 39.1 ppm in Form II 
and 51 ppm in Form III. A large number of reports of polymorph identification by SSNMR exist 
in the literature 13,24.  
The selectivity of SSNMR allows us to distinguish not only between polymorphs, but 
also between API and excipients. Common excipients, including disaccharides such as lactose 
and trehalose, contain substituted rings with oxygen-bonded carbons. The proximity to oxygen, 
an electronegative atom, causes the chemical shift of these carbons to shift to higher ppm values. 
Figure 2.8 shows the 13C SSNMR spectrum of a mixture of ibuprofen and mannitol, another 
common excipient. The peaks from the mannitol appear between 50 and 100 ppm, and there is 
no overlap between these peaks and the ibuprofen peaks.  
2.6.2 Linewidths and peak area 
The linewidths of solids can be used to distinguish crystalline from amorphous materials, 
and the peak areas can be integrated in order to perform quantitation of the components of a 
mixture. The linewidths of the peaks in the SSNMR spectrum of a molecule vary with the  
	  
 39 
 
 
 
 
Figure 2.7 Aliphatic region of the 13C SSNMR spectra of gabapentin polymorphs. a. Form II; b. 
Form III. The chemical shifts, or position of the peaks, in the two spectra are different, allowing 
the distinction of the two forms. Particularly useful in the identification is the nitrogen-split 
carbon peak that is indicated with an asterisk (*) 
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Figure 2.8. 13C SSNMR spectrum of a mixture of ibuprofen and mannitol. The peaks of the API 
(ibuprofen) are separate from the peaks of the excipient (mannitol) 
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number of different conformations assumed by the molecule. Highly mobile materials such as 
amorphous materials have linewidths that may be ten times broader than the linewidths of rigid 
crystalline materials.  
The crystal quality of the solid material can also impact the linewidth of the peaks in the 
SSNMR spectrum. Highly defective crystalline particles of ibuprofen generated by milling were 
shown by Barich and coworkers to have broader linewidths than as-received crystalline 
ibuprofen 14. They have also shown that the presence of certain excipients, such as talc, increased 
the linewidth of the peaks of ibuprofen. This effect was attributed to a phenomenon known as 
anisotropic bulk magnetic susceptibility (ABMS).  
 Quantitation of the amount of each component present in mixtures by integration of peak 
areas in the SSNMR spectrum can be performed by SSNMR when the appropriate acquisition 
parameters are used. The parameters in question include the delay allowed for the material to  
relax and the contact time during cross-polarization. Mixtures of polymorphs have been 
quantified by SSNMR and limits of quantitation as low as 1% have been obtained 23,25. 
2.6.3 Relaxation rates  
Relaxation is the process through which a material returns to equilibrium after an NMR 
pulse and it occurs via various processes, including spin-lattice relaxation and spin-spin 
relaxation. These processes are characterized by relaxation times. NMR relaxation times are an 
indicator of the amount of mobility present in a material.  For example highly mobile amorphous 
materials typically have faster relaxation rates, hence shorter relaxation times, than their highly 
rigid crystalline counterparts. Relaxation rates have been used to study the molecular motions in 
proteins 26. The proton spin-lattice relaxation time (1H T1) is the most relevant to us in this study. 
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2.7 Proton spin-lattice relaxation times (1H T1) 
 Spin-lattice relaxation, or T1 relaxation, refers to the transfer of energy that occurs from 
the excited nuclei to the surroundings; this allows the material to return to equilibrium after an 
RF pulse. The surroundings include other molecules in the samples and the remainder of the 
molecule itself containing the nucleus of interest. T1 relaxation is an exponential process and is 
modeled by the following equation: 
(Nlower-Nupper)= (Nlower-Nupper)equil (1− !
! !!!)   (2.6) 
where Nlower and Nupper are the nuclear populations in the lower and higher energy states 
respectively. The T1 is the time that it takes for the system to return to 63% of its equilibrium 
value through the spin-lattice relaxation process. 1H T1 times can be measured using an 
experiment called a saturation recovery experiment. Figure 2.9 shows a saturation recovery pulse 
sequence. During saturation recovery experiments, a radiofrequency pulse is applied to the 
sample and the amount of time that the material is allowed to return to equilibrium, or relax, is 
varied. That time interval is denoted tau (τ). A designated number of spectra, usually ranging 
from 8 to 32, are acquired at each tau and are summed.  
Figure 2.10 shows a typical 1H T1 plot, in which the intensity of the NMR signal at each τ 
value is plotted versus the τ value. 1H T1 times are often measured instead of 13C or other nuclei 
because the spectra are typically acquired using cross polarization. In addition, because of their 
high natural abundance, protons provide a more global image of the relaxation behavior of the 
material, while 13C times can be used to assess local motions. When using cross polarization 
between 1H and 13C, 1H T1 times can be measured from 13C SSNMR spectra. This is because 
under cross polarization conditions the relaxation of the material is dictated by the relaxation of 
the abundant nucleus. 1H T1 values can range from a few seconds to thousands of seconds.  
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Figure 2.9 Solid-state NMR saturation recovery pulse sequence. This is a common sequence 
used to obtain 1H T1 times while collecting 13C spectra. 
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Figure 2.10 Typical T1 relaxation plot. Plot of the intensity of the peaks in the SSNMR spectrum 
versus the tau time. The data (open circles) was fit to the Equation 2.6 
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A number of factors can affect the magnitude of the 1H T1 relaxation time measured, 
including the presence of relaxation sinks in the material that contribute to a decrease in 1H T1 
time. Fast rotating groups such as methyl, ethyl and t-butyl groups are commonly encountered 
relaxation sinks. Because they are part of the chemical structure of the molecule, they are 
qualified as intrinsic relaxation sinks.  The mobility of the material also tremendously affects the 
1H T1 relaxation, with highly mobile materials such as amorphous frequently having shorter 
relaxation time than crystalline samples. Relaxation sinks can also be present at the bulk level. 
For example, a small amount of amorphous material in an otherwise crystalline material can act 
as a relaxation sink. Water, when it is not hydrogen-bonded, also behaves as a relaxation sink. 
Other factors that have been shown to impact the 1H T1 time are the presence of crystal defects, 
the reduction in particle size of a crystalline material, and the presence of paramagnetic oxygen 
27-29.  
By monitoring the 1H T1 times of mixtures, assessments of the level of miscibility of 
mixtures were also made 30-32. These studies were possible because of a process known as spin 
diffusion that occurs with protons. Spin diffusion is a through space transfer of magnetization 
through dipolar coupling. As a result of spin diffusion, homogeneous solids have one 1H T1 time. 
Heterogeneous mixtures have more than one 1H T1 time. The spin diffusion process is also 
exploited for the measurement of domain sizes in solids. The ability to establish a correlation 
between 1H T1 times and distances is highly relevant to the work presented here and will be 
discussed in more detail in the next chapter. 
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Measurement of Domain Sizes using Solid-State NMR spectroscopy  
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3.1 Introduction 
In this chapter, the use of advanced solid-state NMR techniques to measure distances is 
briefly reviewed, focusing on the distances that can be measured, the systems where these 
techniques have been applied, and the limitations of each technique. The use of spin diffusion for 
distance measurements by solid-state NMR is particularly emphasized because it is the most 
relevant in the study presented in this dissertation as it allows the measurement of longer 
distances. A description of the link between spin diffusion and proton spin-lattice relaxation 
times (1H T1) as cited in the literature will be presented. Finally, the studies previously performed 
in the Munson laboratory using aspirin and lactose as model compounds are summarized, where 
the 1H T1 times of ground and unground materials were determined. The way that they represent 
the starting point for the investigation presented in this dissertation will be underlined. All the 
SSNMR size measurement techniques that are presented are based on exploiting the dipolar 
coupling interactions between nuclei. 
3.1.1 Dipolar coupling 
Dipolar coupling is a through-space interaction between nuclei. The strength of the 
dipolar coupling decreases with the cube of the distance separating the two interacting nuclei 
according to the following relationship: 
!!" =
!!ℏ!!!!
!!!!"
!     (3.1) 
where DIS is the dipolar coupling between two spins I and S, µ0 is the vacuum permeability 
constant, γI and γS are the magnetogyric ratio of spins I  and S, respectively and rIS is the distance 
between the two spins. Spin ½ nuclei with large magnetic moments such as protons have the 
strongest dipolar coupling. The strength of the magnetic moment of a nucleus is evident in the 
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magnitude of its magnetogyric ratio. All of the SSNMR distance measurement methods are 
based on the dipolar coupling that exists between NMR-active nuclei such as 13C, 1H, 19Si, and 
15N, etc. 
The distance separating two NMR active nuclei that are a few angstroms apart from each 
other but isolated from other nuclei can be determined directly by measuring the strength of their 
dipolar coupling (Figure 3.1). Nuclei that are farther apart are very weakly coupled, and 
therefore the distance between them cannot be measured directly because the uncertainty in 
measuring small dipolar couplings is too large. However, dipolar coupling interactions from the 
first nucleus to its nearest neighbor, with additional coupling to the final nucleus of interest can 
be used to measure the distance between the first and the last nuclei (Figure 3.1). This indirect 
way of measuring distances is the concept behind spin diffusion and is only applicable to 
materials containing strongly coupled nuclei that are highly abundant in the sample such as 
protons. Both the direct and the indirect size measurement approaches will be discussed here. 
3.2 Direct distance measurements 
A number of NMR pulse sequences have been developed in order to take advantage of 
the dipolar coupling between two nuclei that are in close proximity to each other to measure the 
distance between them. REDOR (Rotational Echo DOuble Resonance), TEDOR (Transferred-
Echo DOuble Resonance), DRAWS (Dipolar Decoupling With A Windowless Sequence), and 
RFDR (Radio Frequency-Driven Recoupling) are of some of these sequences 1-3. They have been 
applied to measure distances between atoms in biomolecules, biological membranes, and 
inorganic and organic solid materials 1,4,5. Distances probed by REDOR are on the order of a few 
angstroms. Since the accuracy of the measurement is dependent on the strength of the dipolar 
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Figure 3.1. The dashed line represents the dipolar coupling between two nuclei and r the 
distance separating them. Longer distances are accessible through spin diffusion through 
numerous dipolar couplings (bottom figure) than through direct measurement from one dipolar 
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coupling between the nuclei as shown in Equation 3.1, the distances measured are dependent on 
the pair of nuclei studied. 13C-15N distances below 5Å are usually considered reliable. REDOR 
experiments typically require that the atoms of interest be isotopically labeled, which is one of 
the limitations of this technique. 
Cross polarization experiments are another popular means of directly measuring the 
distance separating two close nuclei. In the previous chapter, it was mentioned that cross-
polarization allows us to take advantage of the high natural abundance of nuclei such as 1H to 
more rapidly obtain spectra of dilute nuclei such as 13C 6. Experiments that measure the growth 
in intensity during the cross-polarization time between heteronuclei can be employed to measure 
interatomic distances between them 7,8. During cross-polarization experiments, the nuclei are 
allowed to exchange magnetization with one another for a given amount of time denoted the 
contact time, and an NMR signal is subsequently acquired. The contact time is varied and the 
NMR signal is collected after each contact time. The efficiency of the magnetization transfer 
between the two nuclei is reflected in the intensity of the NMR signal recorded and is indicative 
of the strength of the dipolar coupling between the two nuclei and, as a result, is also indicative 
of the distance separating them. Equation 3.1 is then used to calculate the distance between the 
two nuclei.       
The techniques mentioned so far provide direct distance measurements that are only a 
few angstroms in length; and are only applicable to the measurement of interatomic distances. 
One way to measure longer distances by SSNMR is to take advantage of the strong dipolar 
coupling of protons and their high natural abundance.  
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3.3 Indirect distance measurements - Spin diffusion  
Spin diffusion is the transfer of magnetization between protons through homonuclear 
dipolar coupling. Because protons are 100% abundant and strongly coupled due to their high 
magnetogyric ratio, this magnetization transfer occurs over longer overall distances than the 
heteronuclear couplings discussed earlier. Through SSNMR spin-diffusion experiments, 
distances as small as 0.5-50 nm have been estimated; this is below the resolution of electron 
microscopy 9. Similar distances can be assessed by small angle X-Ray scattering (SAXS) and 
comparison between distances obtained by that technique and SSNMR spin diffusion 
measurements have been performed. Jack and coworkers compared domain size measurements 
of polystyrene-polyisoprene block copolymers obtained by NMR and SAXS. The domains 
ranged from 2 nm to 10 nm in size 10. The authors found that the values for domain sizes 
obtained by both techniques were in very good agreement. Because spin diffusion experiments 
allow such small distances to be characterized, they have been widely employed to measure the 
domain sizes of the components of polymeric blends and other systems including biomolecules 
11-16.  
3.3.1 Spin diffusion experiments 
Spin diffusion experiments consist of monitoring the transfer of magnetization from a 
magnetization-dense region, or source, to a magnetization-poor region, or sink, where it is 
released. The time that it takes for this transfer to occur is dependent on the distance separating 
the source of the magnetization and the sink, and on the speed of the spin diffusion process. The 
transfer of magnetization from one region to the other is assessed by the intensity of the NMR 
signal collected. Therefore, if the rate of the spin diffusion is known, one can estimate the 
distance travelled by the magnetization and the size of the domain by monitoring how the 
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intensity of the NMR signal changes with time. Spin diffusion experiments were first initiated by 
Goldman and Shen on an inorganic material 17.  
Typical spin diffusion experiments include a selection, a mixing, and a detection period. 
One of the components of the material studied is excited during the selection period, while the 
other one is devoid of magnetization. The magnetization is then allowed to travel from that 
magnetization-excess region to a low-magnetization region, and finally the amount of 
magnetization present in the second region is detected in terms of signal intensity. Ideally, each 
component can be easily identified in the NMR spectrum of the mixture by a particular peak 
(Figure 3.2). The detection consists in monitoring the gain, or loss, of intensity of the 
distinguishable peaks. The rate at which the spin diffusion is taking place is given by the spin-
diffusion coefficient.  For a given spin diffusion coefficient, the transfer of magnetization will be 
completed more rapidly over smaller distances than over larger distances. The correlation 
between the intensity of the NMR signal and the amount of time that the magnetization is 
allowed to propagate is depicted by build-up curves that are plots of the intensity versus the 
square root of the time. Typical build-up curves are presented in Figure 3.3. The equation 
correlating the intensity of the NMR signal to the duration of the diffusion has been derived from 
the point diffusion out of a sphere, thus explaining the dependency on the square root of the time 
18. 
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Figure 3.2 Schematics describing basic spin-diffusion experiment. Modified from (19). Two 
polymers A and B are in a blend. Polymer A is selected during the selection portion of the spin 
diffusion experiment, and the intensity of the peaks of A and B in the NMR spectrum is 
monitored as the mixing time is varied and spin diffusion occurs. 
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Figure 3.3 Typical intensity vs √time spin diffusion build up curves. The numbers by the curves 
represent the distance d between the source of the magnetization and the sink.  
 
Reproduced from 19 with permission 
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In practice, the experimental data obtained from the magnetization exchange experiments are 
fitted and a build-up curve is obtained. The spin diffusion coefficient must be known in order to 
perform the simulation. The time at which the magnetization would reach a 100% is then 
extrapolated and plugged into the following equation in order to obtain the size of the domain 18-
20.   
< !! >= 6!"       (3.2) 
where <d2> is the mean square displacement, t is the time and D is the spin diffusion  coefficient. 
The value of the integer in Equation 3.2 varies slightly depending on the morphology of the 
domains in the materials studied 9,18.  
3.3.2 Limitations of spin diffusion experiments 
The spin diffusion coefficients must be known in order to obtain domain sizes. The spin 
diffusion coefficients of a variety of polymers have been measured experimentally. The values 
obtained ranged from 0.2-0.8 nm2/ms, depending on the rigidity of the material and the method 
used to perform the measurements 19,21. The less rigid the material is the smaller the spin 
diffusion coefficient. 
One of the limits of the size measurements performed through SSNMR spin diffusion 
experiment is the proton spin-lattice relaxation rate of the material. During spin-lattice 
relaxation, magnetization is also transferred to a sink. Spin diffusion and spin-lattice relaxation 
occur concurrently. However, if the spin diffusion does not process faster than the spin-lattice 
relaxation, then there are limitations on the size of the domains that can be measured. That is 
because the intensity of the NMR signal collected during the spin diffusion experiment is no 
longer solely dependent on the rate of spin diffusion, but also incorporates spin-lattice relaxation. 
Therefore the maximum domain size that can be measured through spin diffusion is dictated by 
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the magnitude of the 1H T1 time of the material analyzed 19. The majority of polymers are 
amorphous or semi-crystalline; as a result they have very short proton spin lattice relaxation 
times, on the order of a few seconds. The longer distances that have been measured for polymers 
are on the order of 100-200 nm 20,22.  
When spin diffusion occurs faster than the spin-lattice relaxation, it is believed to be 
responsible for the observation of a single proton spin-lattice relaxation time in homogeneous 
solids 23,24. This averaged common relaxation time is specific to protons. For example, all the 13C 
nuclei in a molecule are expected to have different spin-lattice relaxation rates since spin 
diffusion does not occur among 13C. Because of the spin diffusion process, proton spin-lattice 
relaxation times are highly dependent on domain sizes as well. This dependency is exploited for 
the study of the miscibility of polymer blends and pharmaceutical amorphous solid dispersions 
23,24.  
Unlike amorphous polymers, crystalline organic materials can have very long proton 
spin-lattice relaxation times due to their rigidity, and the size of some crystalline solids has been 
shown to impact their 1H T1 times.  However, the ability of SSNMR to measure domain sizes of 
crystalline materials has never been investigated although changes in 1H T1 times of crystalline 
materials have been reported.  
3.4 Changes in 1H T1 times of crystalline solids   
Schieber has shown that the 1H T1 time of ground crystalline aspirin decreased from 55.5 
s to 8.6 s when the material was exposed to high levels of oxygen 25. This was a reversible effect, 
and purging the oxygen out of the materials using N2 gas caused the 1H T1 to return to close to its 
original value. The presence of oxygen had no effect on the 1H T1 time of unground aspirin. 
Schieber hypothesized that, due to the smaller size of the ground aspirin particles and the likely 
	  
	   61 
presence of defects created by the grinding process, the relaxation occurs faster in the ground 
sample because the paramagnetic oxygen, which is a relaxation sink, can penetrate through the 
defects and speed up the relaxation of the material. 
A study by Rabbani and Edmonds indicated that reducing the size of particles of small 
organic materials by grinding led to a decrease in relaxation time of the materials 26. The sole 
objective of the study was to introduce an alternative to the use of paramagnetic impurities to 
reduce the length of SSNMR experiments. Spin diffusion was believed to be responsible for the 
transport of magnetization, referred to as “heat” in the article, from the molecules in the center of 
the particles to the ones on the surface that have a faster relaxation rate, hence a shorter 
relaxation time. Small organic materials were used as models in the study and a mathematical 
model describing the mechanism through which the relaxation occurred was proposed. Several 
reasons why the model and the experimental results did not fully agree were pointed out. They 
include the fact that the particles in the samples produced by ball milling are likely not spherical, 
nor uniform in size or morphology.  The authors also pointed out that the “grains possess 
dislocations” that contribute to increasing the surface area of the particles. As a result, there is a 
larger amount of surface molecules than the one calculated by assuming that particles are perfect 
spheres. These dislocations, like any other imperfections in crystals, are commonly referred to as 
crystal defects. The authors concluded that using their model one could obtain an order of 
magnitude calculation of the size of the grains (particles).  
Finally, previous work in the Munson laboratory has shown that a decrease in relaxation 
time occurred in lactose monohydrate when it was cryoground 27. In that study, Lubach and 
coworkers cryoground crystalline α-lactose monohydrate for different lengths of times and 
obtained 1H T1 times and 13C SSNMR spectra of all the samples. They found that at longer 
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grinding times, crystalline lactose converted to amorphous lactose. This was obvious by the 
significantly broader peaks observed in the SSNMR spectra. Lactose ground for 2 min remained 
crystalline, yet its 1H T1 relaxation times was an order of magnitude shorter than that of the 
unground material. Similarly to lactose, a decrease in 1H T1 times was observed with increasing 
grinding time when aspirin was cryoground 28. However, unlike lactose, aspirin remained 
crystalline regardless of the length of grinding. The reduction in 1H T1 magnitude observed in 
both lactose and aspirin was hypothesized to be due to the creation of crystal defects or the 
reduction in particle size both caused by grinding. These conclusions and the Rabbani study, 
suggest the existence of a correlation between the 1H T1 magnitude of a crystalline material and 
the crystallites size.  
3.5 Conclusion 
In this chapter, ways that solid-state NMR was employed to measure distances and 
domain sizes in a variety of systems have been presented. The size of the majority of the systems 
that have been studied is in the angstrom or nanometer range. Spin diffusion experiments allow 
the measurements of longer distances and domain sizes, and studies suggesting a relationship 
between spin diffusion, the magnitude of the proton spin-lattice relaxation (1H T1) time of a 
material, and the domain size of the material were discussed. In the remainder of this dissertation 
an investigation of the correlation between particle size and 1H T1 time will be presented.  
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4.1 Introduction 
The objective of the work presented in this chapter was to investigate quantitatively the 
correlation between particle size and 1H T1 relaxation time using model compounds. In the 
previous chapter the use of SSNMR to measure distances was discussed. In particular, the 
process of spin diffusion and its utility when measuring distances on the order of hundreds of 
nanometers was shown. Also mentioned at the end of the previous chapter were previous studies 
performed in the Munson laboratory that found that the proton spin-lattice relaxation times (1H 
T1) of both lactose monohydrate and aspirin decreased with the length of time that the material 
were cryoground 1,2. A few hypotheses were proposed to explain the change in 1H T1 time 
observed including the presence of crystal defects created by the grinding process and the 
decrease in particle size of the materials. Here, particles in the µm to nm size range were studied 
because they are more and more commonly encountered during the pharmaceutical drug 
development as particle size reduction is often employed in the pharmaceutical industry during 
manufacturing and is also becoming a means to increase the dissolution rate of poorly soluble 
compounds 3. 
Four specific aims were identified:  
• Identify the desired characteristics of a pharmaceutically relevant model compound 
and choose a suitable compound. 
• Prepare uniformly sized particles of our model compound(s), ranging from a few 
nanometers to a few micrometers in size, with a particle size distribution as narrow as 
possible. 
• Measure the size of the particles in the samples prepared using common particle 
sizing methods such as scanning electron microscopy (SEM).  
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• Characterize the prepared and the as-received materials by solid-state NMR and 
investigate the correlation between 1H T1 and particle size.  
Certain characteristics of lactose and aspirin made it necessary to find other model 
compounds. First, lactose becomes amorphous when processed, and it would not be possible to 
separate the effect of the presence of amorphous material on the 1H T1 time of the material from 
that of any change in particle size. We were also interested in preparing and characterizing 
nanoparticles in this study, and a large number of the nanoparticles preparation techniques 
involve suspending the solid in water, which would not be possible with lactose since it is water 
soluble. Aspirin remained crystalline when ground; however, it is known to undergo hydrolysis 
to salicylic acid and acetic acid, therefore similarly to lactose, sample preparation methods 
requiring the solid to be suspended in water would likely not be an option since aspirin could 
degrade during sample preparation. It is unclear how the presence of salicylic acid in the sample 
would affect the 1H T1 times. Moreover the 1H T1 time of aspirin is still fairly short (60 s); as a 
result it could be difficult to confidently identify small changes in its magnitude as being real, as 
opposed to being within experimental error. 
Based on our experience with lactose and aspirin we have identified the properties 
desired in a model compound for this study. This chapter presents the first two specific aims of 
the study: the model compound selection, and the sample preparation. Both of these aims 
involved the physical state characterization of the as-received and prepared materials. The next 
chapter will present the last two specific aims of this investigation: the size and 1H T1 
characterization and the correlation between the two parameters. 
4.1.1 Desired properties of a model compound 
An ideal model compound for this study will have the following properties.  
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• Has a long 1H T1 relaxation time. Even a small change in magnitude would be easily 
detected with a compound that has a long 1H T1 time ( > 500 s), and less likely to be 
within the error margin of the 1H T1 time measurements. The absence of highly 
mobile groups such as methyl or t-butyl groups in the structure of a material, and the 
presence of rigid groups such as benzene rings are good indicators that it is likely to 
have a long 1H T1 time. 
• No polymorphism. This is to prevent complicating the system with possible 
polymorphic conversions during sample preparation, and to ensure that any change in 
1H T1 NMR relaxation time detected is due to the change in particle size of the 
material, and not the presence of another form. 
• Remains crystalline during processing. This is based on the above-mentioned study 
where lactose monohydrate was used as a model compound to study the impact of 
pharmaceutical processing on 1H T1 relaxation times. Lubach and coworkers found 
that the relaxation time of lactose decreased as they increased the grinding time 
however lactose also became amorphous upon grinding 2. Since amorphous lactose 
was known to have a short relaxation time, its presence alone could have been 
responsible for the decrease in 1H T1 time observed. Therefore no firm conclusion 
could be drawn on the possible impact of particle size on the 1H T1 time. 
• Poorly water-soluble. The objective of the work presented in this dissertation is to 
correlate the size of the particles in a crystalline material to its proton spin lattice 
relaxation time (1H T1), and specifically to engineer particles of the model compound 
in the 100 nm-100 µm size range to correlate them to the 1H T1 time. A number of 
size reduction techniques exist, and the majority of them are best suited for use with 
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poorly soluble compounds. This is because they were developed as a way to increase 
the bioavailability of poorly water-soluble compounds such as BCS Class II and IV 
compounds. As a result, a model compound for this study would most likely be 
poorly water-soluble.  
• Inexpensive. About 200-300 mg of material is needed to fill a 7 mm NMR rotor. 
Considering this relatively large amount of material, a cheap model compound would 
be more economical.  
• Non-toxic. A safe compound is preferred in order to minimize the exposure of the 
students in the laboratory to highly toxic chemicals. 
Once a model compound was chosen, methods to prepare particles ranging from hundreds of 
nanometers to hundred of micrometers were identified. A number of particle size reduction 
methods exist, a brief summary of which is presented in the next section.   
4.1.2 Particle size reduction techniques 
Two main particle size reduction strategies exist: top-down and bottom-up 4. In the 
bottom-up approach, the drug is dissolved in a solvent, and precipitated in an anti-solvent in a 
controlled fashion. Surfactants are often used in order to prevent the particles formed from 
agglomerating. Typical surfactants include block co-polymers such as Pluronics and other 
polymers such as hydroxypropyl methylcellulose (HPMC). Both the type of polymer and the 
ratio of polymer to API are often chosen by trial and error. The difference between the ability of 
different surfactants to stabilize the same materials has been investigated numerous times 4,5. 
Supercritical fluid precipitation and solvent-anti-solvent precipitation are two examples of 
bottom-up methods 6. The suspensions produced are often freeze-dried or otherwise dried to 
obtain a solid final product 7. Several studies evaluated the effect of the preparation method and 
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the influence of different surfactants and stabilizers on the size of the particles obtained, and on 
the physical stability in terms of conservation of the size of particles in the final product 4,8. Still, 
the conclusions appear to be very compound-specific and much remains to be understood in 
order to obtain complete control over the size engineering of particles.  
The top-down approach consists of mechanically reducing the size of larger particles to 
obtain smaller ones. Grinding, high-pressure homogenization and media milling are examples of 
top-down methods. During media milling, the solid is suspended in a non-solvent, usually water, 
and circulated through a chamber where it is milled by small polymeric or ceramic beads. The 
size of the beads and the length of milling can be varied in order to obtain particles of different 
sizes. Top-down size reduction techniques such as milling are often used during manufacturing 
of solid pharmaceuticals in order to increase the powder flow properties of the material.  
Some groups have investigated which of the particle size reduction approach, top-down 
or bottom-up, presents an advantage over the other 4. However, it seems that the best technique 
to use is highly dependent on the material whose size is being reduced as well as on the desired 
final size therefore in this dissertation, a combination of top-down and bottom-up techniques was 
used to prepare particles of the model compounds selected.  
4.2 Materials and Methods 
4.2.1 Materials 
Salicylic acid, and dicumarol were purchased from Sigma Aldrich (St Louis, MO) and used as-
received.  
4.2.2 Sample preparation 
Cryogrinding 
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About 1.5 g of salicylic acid or dicumarol was placed in a vessel and ground while immersed in 
liquid nitrogen after a 15 min precooling period with alternating cycles of 2 min of cooling and 2 
min of grinding (SPEX SamplePrep 6770 Freezer/Mill, SamplePrep, Inc., Metuchen, NJ). The 
rate of grinding was 10 counts per second. The total grinding time was 60 min for salicylic acid 
and 30 min for dicumarol. 
 
Sieving 
 850, 710, 600, 425, 300, 125 and 75 µm sieves were used to separate the particles in as-received 
salicylic acid based on size (USA Standard Sieve 3”).  The sieves were shaken for 15 min on a 
sieve shaker (Gilson company, Inc. Performer III Model SS-3, Lewis Center, OH) set at an 
amplitude of 5. The powder remaining on top of each sieve was then collected, weighed, and 
stored over dessicant at ambient conditions. 
 
Spray drying 
A 5% (w/v) solution of salicylic acid in methanol was spray dried in a Buchi mini spray-dryer 
(Mini Spray-Dryer B-290, Buchi Corporation, New Castle, DE) using the conditions presented in 
Table 4.1. 
 
Anti-solvent precipitation 
In all cases the API was dissolved in a solvent and added to water, or to an aqueous solution of 
surfactant, under sonication (Fisher brand sonic dismembrator, Fisher Scientific, Pittsburgh, PA). 
A Fisher brand injector and a 5mL syringe with a 20-gauge needle (Popper deflected non coring 
septum 20 x 8”, Popper & Sons, Hyde Park, NY) were used for the injections. The suspensions 
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were then lyophilized in a Virtis freeze- dryer (Advantage 2.0 Benchtop Freeze Dryer, SP 
Scientific, Gardiner, NY).  
Salicylic acid- Salicylic acid was dissolved in either acetonitrile or acetone and precipitated in 
aqueous solutions of polyvinyl acetate (PVA) (BASF), Pluronics F 68 (PF 68) (Sigma), or 
hydroxypropyl methylcellulose (HPMC) (Sigma). The ratio of salicylic acid to surfactant was 
always 10:1 and the injection rate was 30 mL/h. The suspensions were then lyophilized. The 
precipitation conditions are summarized in Table 4.2 and the lyophilization cycles used were 
variations of the following cycle: hold at -45 ºC for 360 min; ramp to at -25 ºC and 100 mTorr in 
120 min, ramp to -10 ºC in 480 min at 100 mTorr, hold at -10 ºC and 100 mTorr for 480 min, 
ramp to -5 ºC at 110 mTorr in 240 min, hold at -5 ºC and 100 mTorr for 240 min, hold at 0 ºC 
and 100 mTorr for 360 min, hold at 5 ºC and 100 mTorr for 360 min, hold at 10 ºC and 10 mTorr 
for 60 min.  
Dicumarol-A suspension of dicumarol in dimethyl sulfoxide (DMSO) was stirred and heated to 
at least 100 ºC overnight to obtain a 1mg/mL solution. The solution was then injected into water 
under sonication. The sonication amplitude was 20% for all the samples. Table 4.3 summarizes 
the ratios of DMSO to water, as well as the injection speed employed for each lot prepared. 10-
15 vials were prepared using each set of parameters. After injection, the suspensions were freeze-
dried using the following cycle: hold at -70 ºC for 120 min, extra freezing at -50 ºC for 60 min; 
hold at -5 ºC and 100 mTorr for 1320 min, ramp to 15 ºC in 300 min at 100 mTorr, hold at 15 ºC 
and 100 mTorr for 600 min, ramp to 30 ºC at 50 mTorr for 300 min, hold at 60 ºC and 10 mTorr 
for 60 min. The vials were held at 25 ºC and 200 mTorr until they were removed from the 
lyophilizer. 
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4.2.3 Sample characterization 
 Differential scanning calorimetry (DSC) 
1-4 mg of sample was weighed in a standard, hermetic or T-Zero normal TA aluminum pan. 
Samples were heated from -10ºC to 250 ºC or 300ºC using a 10ºC/min ramp (DSC Q200 or DSC 
Q2000, TA Instruments, New Castle, DE).  
 
Solid-State Nuclear Magnetic Resonance (SSNMR) spectroscopy 
 All the samples were packed under ambient conditions in 7 mm zirconia rotors (Revolution 
NMR, Fort Collins, CO). 13C SSNMR spectra were collected using either a Chemagnetics 
CMX300 (Varian, Palo Alto, CA) or a Tecmag Appolo (Tecmag, Inc., Houston, TX) 
spectrometer both operating at a 13C frequency of ~75 MHz. 3-methylglutaric acid was used as 
an external standard, with the methyl peak referenced at 18.84 ppm 9. All spectra were acquired 
using cross-polarization and magic angle spinning (CP/MAS) 10-13. The magic angle spinning 
frequency was 4 kHz. A SPINAL-64 decoupling pulse sequence was used, and the spinning 
sidebands were suppressed using total sideband suppression (TOSS) 14. A contact time of 1 ms 
was used both for salicylic acid and dicumarol. A 1H decoupling field of 70-80 kHz was used. 
The number of acquisition points was 1024 for both salicylic acid and dicumarol. 1H T1 
relaxation times were measured by saturation recovery.  
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Table 4.1. Salicylic acid spray-drying conditions 
 
Concentration 50mg/mL 
Inlet temperature 150 ºC 
Pump rate 15 mL/min 
Aspirator 100% 
Flow rate 50 
Outlet 
temperature 54 ºC 
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Table 4.2. Conditions employed for anti-solvent precipitation of salicylic acid 
 
Parameters 1 2 3 
Solvent Acetonitrile Acetone Acetone 
Surfactant or 
polymer HPMC PVA Pluronic F 68 
Salicylic acid: 
surfactant (w/w) 5:1 5:1 2:1 
Solvent: water (v/v) 1:10 1:10 1:10 
Injection speed 30 mL/h 30 mL/h 30 mL/h 
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Table 4.3. Conditions used to generate the different lots of dicumarol by anti-solvent 
precipitation of a solution of dicumarol in DMSO into water 
 
 
 
Lot Ratio DMSO: H2O Injection speed 
A 1: 9 60 mL/h 
B 1: 9 30 mL/h 
C 1:1 40 mL/h 
D 1:1 60 mL/h 
E 2:1 40 mL/h 
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4.3 Results and Discussion 
4.3.1 Selection process 
Salicylic acid and dicumarol were identified as model compound candidates based on the 
requirements for a model compound discussed in the introduction. Salicylic acid was considered 
for this study because it has a small rigid structure and lacks mobile groups such as methyl or 
ethyl groups that cause fast relaxation; therefore, it was expected to be a slow relaxer and have a 
much longer 1H T1 relaxation time than aspirin (Figure 4.1a). Salicylic acid is a commonly used 
anti-acne medicine and is therefore safe and cheap, and it has only one known polymorph. 
Similarly, dicumarol is a natural product with only one known polymorph that was used as an 
anticoagulant until it was replaced by warfarin. It has two sets of fused rings in its structure and 
no relaxation sinks; therefore, its 1H T1 relaxation time was anticipated to be fairly long (Figure 
4.1b).  Dicumarol is very poorly water soluble while salicylic acid is not. The comparatively high 
solubility of salicylic acid in water was believed to impact our ability to prepare nanoparticles of 
that material. The first step in the selection process was to confirm that the compounds chosen 
for this study would behave similarly to aspirin when ground, i.e. remain crystalline while their 
1H T1 time decreases. Therefore we cryoground both compounds and characterized the physical 
state and the 1H T1 times of the ground materials. 
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Figure 4.1. Chemical structure of a. salicylic acid; b. dicumarol  
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4.3.2 Effect of cryogrinding on the physical state of the model compound candidates 
DSC and SSNMR were used to characterize the physical state of the materials in order to 
verify that no new polymorph was created, and that no crystalline to amorphous conversion 
occurred as a result of grinding. Figure 4.2 is an overlay of the DSC thermograms of as-received 
salicylic acid and cryoground salicylic acid. An endotherm showing the melting of salicylic acid 
around 160 ºC, the expected melting point of salicylic acid, is present in both thermograms, 
suggesting that ground salicylic acid is crystalline. Other events such as endotherm or glass 
transition that would indicate recrystallization and the presence of amorphous material 
respectively are absent from the thermograms. Small differences in the shape of the endothermic 
peaks can be seen; such differences between the DSC thermograms of a given materials, and the 
presence of shoulders can be attributed to differences in particle morphology and/or particle size 
distribution15,16. Although such differences become relevant when DSC is used to perform 
quantitative studies, here they do not require much concern as DSC is only used as a qualitative 
tool to assess the physical state of  material. The 13C SSNMR spectra of as-received salicylic 
acid and salicylic acid cryoground for 60 min are shown in Figure 4.3. No change in chemical 
shift occurred, however the peaks of the ground materials are significantly broader than those of 
the as-received salicylic acid. Fractures and other defects created by grinding can cause line 
broadening because they decrease the homogeneity of the material.  
 Figure 4.4 shows an overlay of the DSC thermograms of as-received and 30 min 
cryoground dicumarol, and the 13C SSNMR spectra of the same materials. An endotherm 
indicative of the melting of dicumarol around 290 ºC is the only thermal event present. Again the 
small differences between the two thermograms are likely due to particle size or morphology 
differences. Therefore the DSC results suggest that dicumarol remained crystalline upon being  
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Figure 4.2.  DSC thermograms of as-received salicylic acid and 60 min cryoground salicylic 
acid  
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Figure 4.3. 13C SSNMR spectra of a. as-received salicylic acid; b. 60 min cryoground salicylic 
acid  
 
 
 
 
 
 
 
 
a 
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Figure 4.4. DSC thermograms of as-received and 30 min cryoground dicumarol  
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milled. The 13C SSNMR spectra of as-received and 30 min cryoground dicumarol are shown in 
Figure 4.5. The two SSNMR spectra contain the same number of peaks at the same chemical 
shifts, indicating that no polymorphic conversion occurred upon milling. The linewidths of the 
peaks in the three spectra are also very similar, although the peaks of the cryoground samples are 
slightly broader than the ones of the as-received material, as best evidenced by the loss of 
resolution of the split peak at 115 ppm. Similarly to salicylic acid, this is likely due to a decrease 
in sample homogeneity due to grinding. 
4.3.3 Effect of grinding on the 1H T1 relaxation time of salicylic acid and dicumarol 
The 1H T1 time of as-received salicylic acid is approximately 3900 s. The 1H T1 value of 
salicylic acid cryoground for 60 min is 59 s. This represents a decrease in the 1H T1 time of 
nearly two orders of magnitude. Similarly the 1H T1 time of as-received dicumarol is 1500 s, and 
that of dicumarol cryoground for 30 min is 15 s. The SSNMR results demonstrate that grinding 
caused the 1H T1 times of both salicylic acid and dicumarol to decrease, while the materials 
remained crystalline after grinding. Based on the results of the grinding experiments, salicylic 
acid and dicumarol were retained as a model compound for this study.  
Grinding is a quick and efficient way of reducing particle size, and can be employed to 
prepare a large amount of material. However, the particles produced by grinding are not always 
uniform in size. For example, the cryoground salicylic acid particles are uneven chunks with 
rough edges (Figure 4.6a). Although it is obvious they are a few micrometers in size, the lack of 
size uniformity in the cryoground material makes it difficult to accurately estimate the size of the 
particles. Also grinding is known to produce defect-containing particles due to the mechanical 
stress and the heat that it usually generates 17. These defects can contribute to the enhancement of 
the relaxation rate of crystalline materials.  One additional limitation of grinding is that it often  
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Figure 4.5. 13C SSNMR spectra of a. as-received dicumarol; b. 30 min croground dicumarol  
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Figure 4.6. SEM micrograph of a. salicylic acid cryoground for 60 min; b. as received salicylic 
acid  
 
 
 
 
 
 
b. 
a. 
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does not allow the generation of nanometer-size particles. For these reasons grinding was not 
used to generate the samples that would be used for the study of the correlation between particle 
size and 1H T1 time. For the purpose of this study and in order to generate particles in the 
nanometer size range, the ideal size reduction method would generate uniform particles without 
producing crystal defects.  
4.3.4 Preparing uniformly sized particles of salicylic acid over a wide particle-size range 
We wanted to prepare a variety of particle sizes of salicylic acid ranging from larger than 
100 µm to below 1 µm that are uniformly distributed. Thus anti-solvent precipitation, spray-
drying, and sieving were identified as three techniques that could be used to generate particles 
with sizes ≤ 5 µm, 5-100 µm and >100 µm, respectively. In addition, for our study it was 
important that the preparation process not alter the crystalline state of the materials prepared. The 
particles of as-received salicylic acid appear non-uniform in size even to the naked eye, so 
sieving was anticipated to be a good method to separate the particles based on their size (Figure 
4.6b). Table 4.4 summarizes the sizes of the sieve fraction of salicylic acid obtained and the 
relative amounts by weight of material in each sieve fraction. 
The parameters used to perform spray drying, including the solvent, concentration, and 
temperature, were chosen empirically. Since one of the disadvantages of spray drying is the loss 
of material encountered during the process, the conditions used to spray dry salicylic acid were 
chosen both to maximize the yield and to generate particles of the smallest size possible; the 
conditions are presented in Table 4.1. Methanol is a commonly-used solvent for spray-drying 
and was used here as well. The spray-dryer manufacturers indicated that the concentration of the 
solid in solution has a significant influence on the size of the particles in the final product: the 
lower the concentration the smaller the size of the particles obtained. Because spray-drying is  
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Table 4.4. Sieve fractions obtained from sieving as-received salicylic acid.  
 
 
Sieve fraction % of total (weight) 
> 850 µm 19.5 % 
710-850µm 5.4 % 
600-710 µm 6.8 % 
425-600 µm 14.5 % 
300-425 µm 40.6 % 
180-300 µm 11.0 % 
125-180 µm 1.2 % 
<125 µm 1.06 % 
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known to generate amorphous material, it was important to characterize the physical state of the 
material prepared 18. 
Anti-solvent precipitation of salicylic acid was attempted using a variety of solvent-
antisolvent combinations in order to generate smaller size particles. However, all the attempts 
were unsuccessful as the materials produced were not uniform in size. Figure 4.7 shows scanning 
electron microscopy images of salicylic acid samples obtained by anti-solvent preparation. The 
SEM of the samples also suggest that they are not crystalline. The high solubility of salicylic 
acid in water is a possible explanation for our unsuccessful attempts. In all cases, a polymer or a 
surfactant was used in order to stabilize the salicylic acid particles that were generated. Still, 
instead of precipitating, salicylic acid might have been dissolving in the water, and then 
recrystallizing or complexing with the polymer during freeze drying.  
4.3.5 Physical state characterization of the prepared salicylic acid samples 
 Sieving is not expected to change the physical state of the material, and the melting 
endotherms of salicylic acid in the sieved fractions all overlap within 1-2 ºC with the melting 
endotherm of the as received material, as shown by the DSC thermograms in Figure 4.8. The 
DSC thermograms (Figure 4.9) and SSNMR spectra (Figure 4.10) of the spray-dried salicylic 
acid samples indicated that they are crystalline. An endotherm showing the melting of salicylic 
acid is present in the spray-dried samples at the same temperature as the endotherm in the as-
received material around 160ºC. The onset of melting, as well as the shape of the endotherm, is 
also the same in all three materials. Differences in the DSC thermograms of a given materials, 
such as the presence of shoulders has also been attributed to difference in particle morphology15.  
All the peaks in the SSNMR spectra of the spray-dried samples are narrow and at the 
same chemical shifts as the peaks of the as-received material, confirming the crystallinity of the  
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Figure 4.7. SEM micrograph of salicylic acid prepared by anti-solvent precipitation. The 
samples differe by the kind of surfactant or polymer used as well as the ratio of salicylic acid to 
polymer or surfactant. a. salicylic acid : HPMC 5:1; b. salicylic acid : PVA 5:1; c. salicylic acid : 
Pluronic F 68 2 :1 
 
 
 
a.	   b.	  
c.	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Figure 4.8 DSC thermograms of as-received and sieved fractions of salicylic acid 
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Figure 4.9 DSC thermograms of as-received and spray-dried salicylic acid 
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Figure 4.10 13C SSNMR spectra of a. as-received salicylic acid; b. spray-dried salicylic acid  
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spray dried materials. 
4.3.6 Dicumarol samples preparation  
A similar approach to sample preparation as with salicylic acid was attempted with 
dicumarol. However, the size particles of as-received dicumarol (~50 µm) were already below 
the smallest size sieve fraction that we had (75 µm), therefore sieving could not be used. We 
were unable to dissolve dicumarol in solvents that are typically used for spray-drying, such as 
methanol and dichloromethane. Therefore anti-solvent precipitation was used to prepare particles 
of dicumarol of a micrometer and less in size. Although anti-solvent precipitation did not allow 
us to produce particles of salicylic acid in our desired size range, that technique was still 
attempted as a preparation technique for dicumarol. 
Dicumarol is less soluble than salicylic acid in water, which was considered to be an 
advantage for anti-solvent precipitation. However, the precipitation conditions used with 
salicylic acid could not be applied to dicumarol, so a new set of conditions was tried. Table 4.3 
summarizes the precipitation conditions used for dicumarol. DMSO was chosen as a solvent 
because it is the only solvent in which dicumarol could be dissolved. The concentration of 
dicumarol in DMSO was 10 mg/mL in all cases. The solution had to be heated (100º C) and 
stirred for more than an hour in order to ensure complete dissolution. This step was also 
observed by others as being necessary in order to dissolve dicumarol in DMSO (18). Decreasing 
the temperature caused the API to precipitate out of solution, so more concentrated dicumarol 
solutions were not used since they would be even less stable. The sonication amplitude used 
during injection of dicumarol into DMSO was also kept constant at 20% for all samples. This is 
because sonication causes the solution to heat. We wanted to avoid re-dissolving of the drug in 
solution, and a more acceptable alternative was a low sonication amplitude. The parameters that 
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were modified from one sample to the other were the speed of the injection of the dicumarol 
solution into water and the ratio of DMSO to water. The rate of injection of the solvent into the 
anti-solvent has been shown to impact the size of the final particles obtained for a number of 
pharmaceutical compounds 8. Faster injection rates usually yield to larger particles. While only 
the preparation and physical state characterization of the materials are presented in this chapter, 
the ultimate goal was to generate particles of a variety of sizes. 
The ratio of solvent to anti-solvent was also varied. This was done for two reasons: first 
that ratio impacts the size of the particles generated by changing the degree of supersaturation in 
the final solution; and second a large amount of material (200-300 mg) is needed for solid-state 
NMR analysis, and using larger volumes of the dicumarol solutions would yield more product. 
Surfactants were not used because their effect on the 1H T1 relaxation rate of dicumarol is 
unknown. The absence of surfactant would likely cause the particles prepared to agglomerate, 
which is acceptable in this study since the primary focus is not the drug delivery and dissolution 
properties of our material but rather its physical state.  
All of the suspensions were lyophilized following precipitation in order to obtain a solid 
product. Lyophilization was chosen other drying methods such as spray-drying because it does 
not cause any loss of material. Although there are reports of lyophilization from DMSO, no 
report on freeze-drying from mixtures of DMSO and water was found 19. However, a study 
published in 1966 warned against significant lower freezing point of mixtures of DMSO and 
water at certain ratios, compared to the individual components 20.  The authors found that 
mixtures with a 0.2-0.4 mole ratio of DMSO froze below -100ºC. However, such low 
temperatures were not needed in order to freeze the samples prepared here. Moreover, in order to 
test the efficiency of the cycle at removing all of the liquid phase, mixtures of DMSO and water 
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in the ratios used during the precipitation were freeze-dried. All the vials were empty to the 
naked eye at the end of the cycle, as a result the cycle was considered acceptable and was used to 
freeze-dry all the dicumarol suspensions.  
4.3.7 Physical state characterization of the prepared dicumarol samples  
The DSC thermograms of the precipitated samples showed that dicumarol in the 
precipitated lots melted a few degrees lower than the bulk material (Figure 4.11). This is likely 
due to the significant particle size difference between the bulk and the precipitated materials. The 
onset of melting was also slightly different for all the materials, and the melting endotherms of 
the precipitated lots with an early melting onset are broader than the endotherms of the other 
materials.  
The 13C SSNMR spectra of the precipitated materials are shown in Figure 4.12. All the 
peaks in the spectra of the precipitated lots have a similar linewidths to the as-received material, 
confirming that they are crystalline. The peaks in the spectra also have the same chemical shifts 
as the as-received dicumarol, indicating that no apparent polymorphic conversion occurred. The 
spectra of the five precipitated lots presented in Figure 4.13 have poor signal to noise ratio 
because they were extracted from the 1H T1 relaxation data sets, which were collected with a 
small number of acquisitions. That poor signal to noise ratio could explain the differences in 
resolution observed between samples. The difference is most obvious in the splitting of the peak 
at 123 ppm. The splitting is not apparent in Lots A, C, D and E, whereas it is easily seen in lot B 
and the as-received material.  
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Figure 4.11 DSC thermograms of precipitated samples of dicumarol 
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Figure 4.12 13C SSNMR spectra of a. as-received dicumarol, b. Lot A, c. Lot B, d. Lot C, e. Lot 
D, f. Lot E 
 
 
a.	  
b.	  
c.	  
d.	  
e.	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4.4 Conclusions 
Salicylic acid and dicumarol were chosen as model compounds for the rest of this study 
based on the fact that they both have long 1H T1 times, 3900 s and 1500s, respectively, that 
decreased upon grinding. Sieving was used to prepare crystalline particles of salicylic acid 
greater than 100 µm. Anti-solvent precipitation of dicumarol from a DMSO solution into water 
generated crystalline particles in the micrometer and nanometer size ranges. The materials 
prepared and characterized here were used in order to investigate the correlation between particle 
size and 1H T1 relaxation time as described in the next chapter.  
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Chapter 5                                                                                               
Investigation of the relationship between crystallite size and proton spin-
lattice relaxation (1H T1) times of salicylic acid and dicumarol 
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5.1 Introduction 
In this chapter, the correlation between the size of crystalline particles of salicylic acid 
and dicumarol and their proton spin-lattice relaxation (1H T1) times was investigated. The 
theoretical relationship between the two parameters is first discussed, followed by the 
characterization of the particle size and 1H T1 times of the materials. Finally, the relationship 
between the two parameters in the model systems was compared to the theoretical model. The 
samples whose 1H T1 times measurements and particle size characterization are presented in this 
chapter were prepared as described in the previous chapter. Their physical state characterization 
was also described in the previous chapter.  
5.2 Materials and Methods 
5.2.1 Sample preparation 
The preparation of both dicumarol and salicylic acid samples by anti-solvent precipitation, 
sieving and spray-drying were presented in Chapter 4 in §4.2.2. 
5.2.1 Sample characterization 
Laser diffraction. Laser diffraction measurements were performed by Dr. Joseph Lubach at 
Genentech. A Malvern 2000 Mastersizer was used. The powders were suspended in hexane and 
sonicated for 2 min in the measuring chamber before each measurement. The refractive index of 
dicumarol was calculated using the ACD Labs software. 
 
Scanning electron microscopy (SEM). The samples were mounted on an SEM stage line with 
carbon tape, and coated with approximately 30 nm of gold or 15 nm of a gold-palladium mixture. 
The samples were imaged on a Hitachi-S3200-N scanning electron microscope (Hitachi High 
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Technologies America, Inc., Schaumburg, IL). The size of the particles imaged by SEM was 
estimated using a ruler and the scale of the images. 
 
Solid-State NMR spectroscopy. All the samples were packed under ambient conditions in 7 mm 
zirconia rotors (Revolution NMR, Fort Collins, CO). 13C SSNMR spectra were collected using 
either a Chemagnetics CMX300 (Varian, Palo Alto, CA) or a Tecmag Apollo (Tecmag, Inc., 
Houston, TX) spectrometer both operating at a 13C frequency of ~75 MHz. 3-methylglutaric acid 
was used as an external standard, with the methyl peak referenced at 18.84 ppm 1. 1H T1 
relaxation times were measured by saturation recovery. All spectra were acquired using cross-
polarization and magic angle spinning (CP/MAS)2-4. The magic angle spinning frequency was 4 
kHz. A SPINAL-64 decoupling pulse sequence with total sideband suppression (TOSS) was 
used 5. A contact time of 1 ms was used and a 1H decoupling field of 70-80 kHz were used. The 
number of acquisition points was 1024 for both dicumarol and salicylic acid. 
 
5.3 Results and Discussion 
5.3.1 Particle size-proton spin-lattice relaxation (1H T1) time correlation--theory 
In Chapter 3, the relationship between spin-lattice relaxation times and spin diffusion of 
nuclear magnetization was described. As shown previously, spin diffusion is the mechanism 
through which nuclear magnetization is transferred through the sample to reach relaxation sinks. 
The following equation can be written to describe the rate of spin diffusion 6,7: 
<d2>= 6Dt    (5.1) 
where d is the maximum path length of the magnetization, D is the spin diffusion coefficient and 
t is the time during which the diffusion process occurs. The distance d in Equation 5.1 can also 
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be described as the maximum distance from the source of magnetization to the relaxation sink 
(Figure 5.1). The relationship described in Equation 5.1 has been employed to measure domain 
sizes up to 200 nm of polymers in blends of different polymers. In those systems, the 
magnetization is traveling from one polymer in the blend to the other, where the latter constitutes 
the relaxation sink. In rigid systems with long proton spin-lattice relaxation (1H T1) times (> 
10s), the time t in Equation 5.1 would correspond to the spin-lattice relaxation time 8,9. 
Dicumarol and salicylic acid are such systems with relaxation times of 1500 s and 3900 s, 
respectively. In samples containing crystalline particles of only pure dicumarol or salicylic acid, 
the relaxation sink is expected to be the surface of the particles, and therefore the distance d in 
equation 5.1 would correspond to the size of the particles, and smaller particles would be 
expected to have shorter 1H T1 times (Figure 5.1).  Assuming a diffusion coefficient of 0.2 
nm2/ms, which is the value that is expected for rigid polymers and should be applicable to rigid 
crystalline organic compounds, a log-log plot of the square root of the 1H T1 time versus the size 
of the particles can be constructed using Equation 5.1 (Figure 5.2) 6. In such a plot, the slope 
describing the correlation between 1H T1 time and particle size is 1 and the y-intercept is 1.46. 
The following equations describe the mathematics involved to arrive to that conclusion. 
<d2> = 6D(1H T1) 
(1H T1) = <d2> / 6D 
(√1H T1) = d / √(6D) 
Log (√1H T1) = log d – log (√6D)   (5.2) 
 The implication of this slope and y-intercept is that single crystal, or crystallite, sizes of 
approximately 100 nm would have a 1H T1 time of approximately 8 s. Particle sizes of 1 µm are  
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Figure 5.1 Schematics depicting spin-diffusion as a spin-lattice relaxation mechanism inside a 
crystalline particle. The nucleus in red is an excited nucleus carrying excess magnetization. That 
excess magnetization is being carried to a relaxation sink via proton-hopping mechanism or spin-
diffusion (red dashes). For larger particles (a) the distance d from the source to the relaxation 
sink is longer than it is for smaller particles (b)
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Figure 5.2 Theoretical log-log plot of √1H T1 vs particle size, assuming a diffusion coefficient D 
of 0.2 nm2/ms 
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expected to have a 1H T1 time of 830 s and particles of 10 µm in size would have a 1H T1 time of 
83000 s. Since to the best of our knowledge no crystalline organic compound has ever been 
observed to have a 1H T1 time of 83000 s, it is likely that this correlation does not hold for 
particle sizes greater than 10 µm. In the next sections, the results obtained with salicylic acid and 
dicumarol and the way that they differ from the above-described model will be presented. 
5.3.2 Particle size characterization of precipitated dicumarol using SEM and laser diffraction 
SEM images of the five lots of precipitated dicumarol samples prepared as described in 
Table 5.1 are presented in Figure 5.3. Using the scale on the images, the approximate size of the 
particles in the materials was calculated and the results are summarized in Table 5.3. The size of 
the majority of the particles in the precipitated materials as estimated by SEM ranges from 0.5 to 
1 µm. However, larger particles estimated to be 2 µm and 8 µm can be seen in the micrographs 
of lot C and lot D. The as-received dicumarol particles measure approximately 50 µm. The size 
of the particles in Lot B could not be estimated as well as the size of the particles in the other 
samples due to the poor resolution of the SEM micrograph, however it is obvious that the 
particles measure less than 5 µm. The poor resolution could be due to a non-uniform coating of 
the material before SEM analysis.  
Laser diffraction data for all the samples are also presented in Table 5.3. As discussed in 
Chapter 2, the d 0.1, d 0.5 and d 0.9 values represent the size below which 10 %, 50 % and 90 % 
of the sample lies (by volume), respectively. The d 0.5 values range from about 3 µm to 
approximately 5 µm for the precipitated materials. The laser diffraction particle size values are 
significantly larger than the ones obtained from SEM. One possible reason for the lack of 
agreement between the two techniques is that laser diffraction analysis actually measured the 
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Figure 5.3 SEM images of as-received and precipitated dicumarol denoted Lots A through E
Lot A Lot	  B	  
Lot C Lot D 
Lot E As-received 
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Table 5.3 Mean particle sizes of as-received and precipitated dicumarol obtained by SEM and 
laser diffraction 
 
 
 
 SEM 
Laser Diffraction 
d 0.1 d 0.5 d 0.9 
Lot A 0.5 µm 1.6 µm 4.9 µm 18.0 µm 
Lot B N/A 0.9 µm 4.8 µm 19.0 µm 
Lot C 2 µm 0.5 µm 0.9 µm 2.8 µm 20.0 µm 
Lot D 0.7 µm 8 µm 1.2 µm 3.8 µm 16.5 µm 
Lot E 1 µm 1.0 µm 3.3 µm 13.3 µm 
As-received 50 µm 10.9 µm 23.8 µm 43.3 µm 
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size of the agglomerates rather than the size of the individual particles. As seen in the SEM 
micrographs (Figure 5.3), most of the dicumarol particles in the precipitated samples are 
agglomerated. That is likely due to the fact that no surfactant was used during precipitation. All 
of the materials were sonicated for 2 min before laser diffraction measurements; however, it is 
possible that this step did not break down all of the agglomerates. Another possible reason for 
the discrepancy in particle size measurements between laser diffraction and SEM is the non-
uniformity in particle size distribution of the samples. As already mentioned, two of the 
precipitated lots (lots C and D) contain particles both larger and smaller than 1 µm. The presence 
of both big and small particles in a sample is known to skew the results of laser diffraction 
measurements and this is illustrated by the obvious disagreement between the particle size 
distribution of lots C and D and the d 0.5 values (Figure 5.4) 10. Both materials present a bimodal 
size distribution with the smaller range of particle sizes constituting the majority of the sample, 
and therefore cannot be accurately represented with just one particle size. Since the results 
obtained by laser diffraction did not accurately reflect the size of the particles of dicumarol, SEM 
was the only particle sizing technique used henceforth. 
5.3.3 Particle size characterization of salicylic acid samples 
Samples of salicylic acid were prepared using spray-drying and particles of saclicylic 
acid were separated sieving. The particles generated by spray-drying were smaller than the ones 
obtained by sieving, and as a result, the samples prepared required analysis by SEM. SEM 
micrographs of the spray-dried salicylic acid samples are shown in Figure 5.5. The particles have 
an irregular morphology, which makes it difficult to accurately estimate their size. Nonetheless 
they can be estimated at 5 µm for the smaller particles and 20 µm for the larger ones.The sieved 
particles of salicylic acid ranged from less than 125 µm to larger than 850 µm in size as shown in  
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Figure 5.4 Laser diffraction curves of two samples of precipitated dicumarol: a. Lot C; b. Lot D 
a 
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1.       2. 
 
 
Figure 5.5 SEM micrographs of spray-dried salicylic acid. The numbers below the pictures 
indicate samples (1) and (2) of spray dried salicylic acid 
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Table 5.4 Sieved salicylic acid fractions. The median of each sieved fraction was obtained and 
used to construct the plot presented in Figure 5.6 
 
 
Sieved samples Median 
75-125 µm 100 µm 
125-300 µm 212.5 µm 
180-300 µm 240 µm 
300-425 µm 362.5 µm 
425-600 µm 512.5 µm 
600-710 µm 655 µm 
> 850 µm 850 µm 
 
 
 
 
 
 
 
 
 
 
 
	  
	   117 
Table 5.4. The size of the particles obtained was limited both by the mesh sizes available 
and the size of the particles in the starting material.  
5.3.4 1H T1 times of dicumarol and salicylic acid materials 
The 1H T1 times of precipitated lots A-E of dicumarol were measured and are summarized 
in Table 5.5. The 1H T1 times of all the samples prepared by precipitation are shorter than the 1H 
T1 time of as-received dicumarol (1500 s), which is consistent with the expectation that the 1H 
T1 time of crystalline materials decreases with particle size. More specifically, the 1H T1 times of 
the precipitated samples range from 16 s to 520 s. Two samples, lots C and D, had two distinct 
1H T1 times. That is because the relaxation of these materials is not uniform; instead, two 
relaxation profiles are present and they are each characterized by a distinct 1H T1 time. It is 
important to note that these two samples were also the one whose particle size distribution was 
bimodal as shown by laser diffraction; the detection of two 1H T1 times is consistent with this 
distribution.  
The 1H T1 times of the sieved fractions of as-received and spray-dried salicylic acid 
samples were measured and are summarized in Tables 5.6 and 5.7. The 1H T1 time of salicylic 
acid mostly increased as the size of the sieve fraction increased. The 1H T1 time of the largest 
fraction (> 850 µm) is 6100 s while the 1H T1 time of the smallest fraction (75-125 µm) is 3300 s. 
Two 1H T1 times were detected for each of the spray-dried materials: for the first spray-dried 
sample 1H T1 times of 1000 s and 65 s were measured, and for the other one the values obtained 
were 620 s and 100 s.  
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Table 5.5 1H T1 times of dicumarol- The percentages in parenthesis after the relaxation time 
represent the amount of material having that relaxation time in the sample. For Lots C and D the 
longer 1H T1 value detected was assigned to the larger particle size present in the material. This 
was done based on the assumption that 1H T1 time decreases with particle size. 
 
 
 
 size (SEM) 
1H T1 √1H T1 
Lot A 0.5 µm 20 s ± 2 4.5 
Lot B N/A 20 s ± 3 4.5 
Lot C 0.5 µm 2 µm 
16 s ± 3 (40 %) 
68 s ± 8 (60 %) 
4.0 
8.2 
Lot D 0.7 µm 8 µm 
49 s ± 6 (76 %) 
520 s ± 280 (24 %) 
7.0 
22.8 
Lot E 1 µm 80 s ± 7 8.9 
As-received 50 µm 1500 s 38.7 
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Table 5.6 1H T1 times of sieved salicylic acid. The errors indicated are the errors of the fit 
 
 
Sieved samples 1H T1 (s) √1H T1 
75-125 µm 3300s ± 430 57.4 
125-300 µm 3900s ± 270 62.4 
180-300 µm 4000s ± 300 63.2 
300-425 µm 3700s ± 300 60.8 
425-600 µm 5300s ± 510 72.8 
600-710 µm 5900s ± 400 76.8 
> 850 µm 6100s ± 550 78.1 
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Table 5.7. 1H T1 times of spray-dried salicylic acid. The percentages in parenthesis after the 
relaxation time represent the amount of material having that relaxation time. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Size (SEM) 1H T1 
1 20  µm 5  µm 
620 ± 51s (69%) 
65 ± 10 s (31%) 
2 20  µm 5  µm 
1000  ± 250s (70%) 
100 ± 38 s (30%) 
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5.3.5 1H T1 times- particle size correlation—salicylic acid 
Figure 5.6 shows a log-log plot of the square root of the 1H T1 times of the salicylic acid 
samples versus the size of the particles and includes both the spray-dried and the sieved samples. 
The median size of the sieve fraction was used for plotting the sieved salicylic acid samples 
except for the greater than 850 µm fraction. From the shape of the plot it is difficult to determine 
the kind of correlation that exists between the 1H T1 times and the particle size. It appears to be a 
two-regime linear relationship, and indeed each set of data can be described by a linear trend 
line. The slope and the y-intercept of the trend line describing this correlation are 0.14 and 1.5 
for the sieved salicylic acid, and 0.82 and 0.38 for the spray-dried samples, respectively. Because 
the plot of the spray-dried salicylic acid contains only two samples, these samples will not be 
included in the remainder of the discussion, although the results are consistent with later 
conclusions drawn in this chapter. 
5.3.6 1H T1 times- particle size correlation—dicumarol 
Figure 5.7 is a log-log plot of the square root of the 1H T1 times of dicumarol versus the 
size of the particles. Because the results obtained from laser diffraction were not believed to 
accurately represent the size of the particles in the dicumarol materials, the particle size obtained 
by SEM were used to construct the plot. The dicumarol plot was constructed using both the 
precipitated samples and the as-received material. For the two lots that presented two 1H T1 
times, the larger particles seen in the SEM micrographs were assigned to the longer 1H T1 time 
and the smaller ones to the shorter 1H T1 time. The data can be described with a linear trend line 
whose slope is 0.46 and y-intercept is 0.87.  
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Figure 5.6. Log-log plot of the square root of the 1H T1 time of salicylic acid versus the size of 
the particles 
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Figure 5.7 Log-log plot of the square root of the 1H T1 time of dicumarol versus the size of the 
particles 
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5.3.7 Comparison between theoretical model and experimental results of dicumarol and salicylic 
acid 
In order to visualize how the results obtained with our samples compare with the theory, 
a log-log plot of the square root of the 1H T1 time versus particle size that includes the theory and 
our data was constructed (Figure 5.8). The experimental data are below the theoretical 
description of the spin diffusion, indicating that the relaxation times of our samples are shorter 
than predicted by the theory. In addition, the slopes of the data are also different from each other 
and from the theoretical slope of 1: for dicumarol, the slope of the line is close to 0.5, and for 
sieved salicylic acid the slope is close to 0.15. This means that for our model compounds, the 1H 
T1 times increase more slowly with the size of the particles than predicted by the model.  
We suspect that in the dicumarol and salicylic acid particles, relaxation sinks other than 
the surface of the crystals exist. These relaxation sinks may be crystal defects such as grain 
boundaries or line defects 11. As the spin diffusion process occurs, the diffusing magnetization 
will begin to interact with these defect sites before it reaches the surface; this leads to a faster 
relaxation rate and shorter relaxation time than predicted. In dicumarol, the density of the 
relaxation sinks is not believed to be very high, and the resulting spin diffusion rate corresponds 
to the distance, or particle size, being proportional to relaxation time instead of the square root of 
relaxation time. If the distance is proportional to the relaxation time instead of the square root of 
the relaxation time the slope is expected to be 0.5; this is consistent with the dicumarol data that 
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Figure 5.8 Log-log plots of the square root of the 1H T1 time versus particle size. The spin 
diffusion-based theoretical line (blue) as well as the dicumarol and salicylic acid data are present 
on the plot.  
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have slope of 0.46. In salicylic acid, however, there might be more defects and the distance, or 
particle size, is closer to being proportional to the cube of the relaxation time; this would 
correspond to a slope of 0.16. The slope obtained with the salicylic acid data is 0.14.  
Considering the difference between our experimental data and the spin-diffusion based 
theory of the correlation between particle size and 1H T1 times, it is useful to investigate the 
possible role of other relaxation mechanisms in dicumarol and salicylic acid that could be 
responsible for the changes in the 1H T1 times observed. 
5.3.8 Understanding the spin-lattice relaxation of dicumarol and salicylic acid particles 
Factors that can cause decreases in 1H T1 times include the presence of relaxation sinks, 
such as solvent molecules that are not hydrogen-bonded to the solid molecules or amorphous 
material. Although increases in temperature can also cause decrease in 1H T1 times, NMR data 
for all the as-received and processed samples were obtained under the same conditions; therefore 
temperature is most likely not the reason for the reduction in 1H T1 time observed. Moreover, the 
increase in temperature that occurs as a sample is spun at 4 kHz in the NMR spectrometer was 
shown to be very small 12. The physical state characterization of the materials presented in 
Chapter 4, specifically the DSC data (Figures 4.9, 4.10 and 4.12), revealed that no amorphous 
material was present in either the salicylic acid or dicumarol materials. Also, thermogravimetric 
analysis of the materials did not indicate the presence of any significant amount of residual 
solvent in the samples; lots A and B seemed to have a little more than the other samples of 
dicumarol (~5-10%), and for these two lots it is possible that water played a small role in the 
decrease in 1H T1 time (Figure 5.9).  
Crystal defects are also believed to act as relaxation sinks. Therefore high-quality single crystals 
are anticipated to have significantly longer proton spin-lattice relaxation times than defect-
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containing crystals. Salicylic acid was recrystallized from ethanol in order to obtain high quality 
single crystals and compare their 1H T1 times to the value obtained for the as- received and 
sieved samples of salicylic acid. Recrystallization was not performed with dicumarol because it 
is insoluble in the majority of commonly used organic solvents. The recrystallized crystals of 
salicylic acid appear to be single crystals under polarized light and have a needle morphology. 
They measure 500 µm or longer as seen on the SEM images of the particles (Figure 5.10). 
Compared to the sieved salicylic acid samples, the crystals of salicylic acid obtained by 
recrystallization from ethanol are more uniformly sized and shaped; they are also larger in size. 
The 1H T1 time of the recrystallized sample was best described with two 1H T1 times: 2700 ± 300 
s and 710 ± 50 s versus 4900 s for the larger than 850 µm sieve fraction of salicylic acid. The 1H 
T1 times of recrystallized salicylic acid are lower than expected if we argue that crystal quality 
plays a significant role in the proton spin-lattice relaxation of the material and that higher quality 
crystals should have a longer 1H T1 time. It is possible that the needle morphology of the 
recrystallized salicylic acid has a significant impact on the proton spin-lattice relaxation of the 
material: if the surface is the only relaxation sink present, the relaxation can reach that sink in 
both the longer and the shorter dimension of the crystal. Therefore when comparing the size of 
the crystals, it may be that the smaller dimension of the needles is the most relevant. 
Unfortunately we were not able to measure the size of the smaller dimension of the particles 
even by SEM. 
In order to further investigate the presence and role of crystal defects on the spin-lattice 
relaxation of the salicylic acid materials, a surface analysis of the sieved salicylic acid was 
performed using a BET surface analyzer with the expectation that the presence of defects could 
potentially increase the surface area of the materials. Table 5.8 summarizes the BET results. 
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Figure 5.9 Thermogravimetric analysis thermogram of a. dicumarol samples, b. spray-dried 
salicylic acid 
a 
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Figure 5.10 SEM of recrystallized salicylic acid 
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Table 5.8 BET surface analysis results of sieved salicylic acid 
 
 
Sieved samples BET surface area 
< 125 µm 0.3 ± 0.05 m2/g 
300-425 µm 0.0 ± 0.0 m2/g 
425-600 µm 0.0 ± 0.0 m2/g 
600-850 µm 0.0 ± 0.0 m2/g 
> 850 µm 0.0 ± 0.0 m2/g 
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Except for the < 125 µm sieve fraction, the surface area obtained was zero. This might be 
because of a combination of not enough material being used to perform the measurements and 
the small surface area of the particles in the larger sieve fractions. This result suggests that if 
defects are present, they do not cause a significant increase in surface area. There are four 
different kinds of defects that can exist in crystals: point defects, line defects, planar defects or 
volume defects 13. It is possible that point defects are the kind of defects present in the salicylic 
acid particles. BET analysis was not performed with the precipitated dicumarol materials 
because of lack of material. 
Other possible reasons for the decrease in 1H T1 time, such as the presence of 
paramagnetic oxygen, were investigated with dicumarol 14. Oxygen is believed to act as a surface 
relaxation mechanism, by behaving as a relaxation sink for the excited spins that are at the 
surface: once the excess magnetization is carried through the material to the surface by spin 
diffusion, it is possible that the oxygen then absorbs the excess magnetization and allows the 
material to relax. However, the ability of oxygen to enhance the spin-lattice relaxation of a solid 
is limited by the material’s internal relaxation mechanisms. In other words, if there are enough 
internal crystal defects or mobility, then the relaxation time will be unaffected by the presence of 
surface oxygen. That is the reason why Schieber saw little to no decrease in 1H T1 time when as- 
received crystalline aspirin was purged with oxygen 14. The rate at which the magnetization 
reaches the surface or other relaxation sinks is dictated by the rigidity of the material and the 
efficiency of spin diffusion. In order to determine how the level of oxygen affects the spin-lattice 
relaxation of dicumarol, a rotor packed with as-received dicumarol was purged with pure oxygen 
and the 1H T1 time of the material was measured. The 1H T1 time was the same as as-received 
dicumarol packed under ambient oxygen conditions. The 1H T1 time of dicumarol cryoground for 
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8 min was also measured after the material was purged with oxygen. Under these conditions the 
1H T1 time of the material was the same as under ambient oxygen conditions (8 s). These results 
suggest that the mechanisms of internal relaxation are dominant when it comes to the spin-lattice 
relaxation of dicumarol.  
Experiments were performed in order to estimate the impact of the spin-diffusion rate on the 
spin-lattice relaxation of dicumarol and salicylic acid. First the 1H T1 time of a sample of 
dicumarol was measured at several magic angle spinning speeds. Because salicylic acid already 
has such a long 1H T1 time, spinning speed experiments were performed only using dicumarol. At 
faster spinning speeds, the dipolar coupling interactions are weaker, and as a result the efficiency 
of the spin diffusion is expected to decrease and the spin lattice relaxation time would increase 
15. However, it should be noted that at higher spinning speeds the temperature of the sample is 
expected to be higher, and this could also cause longer spin-lattice relaxation times. Tables 5.9 
summarizes the 1H T1 times of a sample of dicumarol prepared by precipitation obtained using at 
4, 8 and 10 kHz magic angle spinning speeds. The material was only packed once and the same 
rotor was used at all spinning speeds. The 1H T1 times of the dicumarol sample range from 34 s 
to 45 s. However, the longer 1H T1 time, 45 s, was not obtained at the highest spinning speed but 
at 8 KHz. Nonetheless the 1H T1 times obtained at 8 and 10 KHz are both longer, by at least 2 s, 
than the 1H T1 time obtained when the sample was spun at 4KHz. 
Magnetic field strength can also impact the spin-diffusion rate. The 1H T1 time of a rigid 
crystalline material is expected to increase a small amount with field strengths because the field 
strength affects the resonance frequency between two nuclei. This is illustrated in the larger 
chemical shift differences between nuclei in a sample at higher fields. The 1H T1 time of a rigid 
material at 400 MHz is expected to be larger than at 300 MHz 16. The 1H T1 times obtained for 
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Table 5.9 Precipitated dicumarol 1H T1 times measured at three different magic angle spinning 
speeds 
 
5 mg/mL dicumarol precipitated 
Spinning speed 1H T1 
4 KHz 34 s ± 5 
8 KHz 45 s ± 3 
10 KHz 37 s ± 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
	   134 
three fractions of sieved salicylic acid using a 400 MHz spectrometer are slightly longer (1.1-
1.2x) than the ones obtained on the 300 MHz spectrometer (Table 5.10). This is consistent with 
the spin diffusion model, where the relaxation times would be slightly longer at higher fields. 
5.3.9 Proposed model 
The results obtained with dicumarol and salicylic acid provide guidance as to how other 
materials will behave. The fact that the spray-dried salicylic acid and precipitated dicumarol 
samples are approximately the same size range and can be described with a similar slope as seen 
in Figure 5.8 supports the universality of the data. If we assume that the correlation between 1H 
T1 time and particle size displayed by dicumarol and salicylic acid is representative of the ranges 
occupied by the particles of each materials, we can propose a model that describes the correlation 
between particle size and 1H T1 time. The dicumarol line crosses the theoretical line at 
approximately a particle size of 100 nm, and the salicylic acid line at a particle size of about 74 
µm. This suggests that up to 100 nm in size, the particles may follow the theoretical line. At 
particles 100 nm or greater, the slope of the line changes, indicating the crystal defects may start 
to increase. The change in slope again at approximately 74 µm indicates that there is a higher 
propensity for internal relaxation for these materials. As noted earlier the correlation between the 
1H T1 time and the particle size of dicumarol and salicylic acid were thought to approach a linear  
and a cube correlation respectively. This translates into the following equations, where the y-
intercepts obtained with our data were used in this proposed model. 
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Table 5.10 1H T1 times of salicylic acid samples measured on a 300MHz and a 400 MHz 
spectrometer 
 
Sieved salicylic acid 180-300 µm 
Magnet strength 1H T1 
300 MHz 4000s ± 295 
400 MHz 5074s ± 365 
 
Sieved salicylic acid 300-425 µm 
Magnet strength 1H T1 
300 MHz 4220s ± 485 
400 MHz 4939s ± 382 
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d < 100 nm;       log √1H T1 =  log d +1.46 
100 nm < d < 74 µm;   log √1H T1 = 0.5log d + 0.8 
d > 74 µm;     log √1H T1 = 0.16 log d + 1.46 
The physical meaning behind these potential correlations is not clear at this point, but is believed 
to be due to defect density. 
Although the spin diffusion theory as only been applied to polymeric systems, its theory 
is well established and based on the properties of nuclei and of the material (rigidity). As a result 
although a quadratic of cubic equation could potentially be employed to fit the salicylic acid and 
dicumarol data, such equation would have no physical meaning. Nonetheless, since the model is 
only based on two compounds, salicylic acid and dicumarol, investigation of other compounds 
would be helpful in determining the strength of the model proposed. Figure 5.11 is a plot of the 
proposed model overlapped with the salicylic acid and dicumarol data. 
5.4 Conclusions 
A correlation between the size of crystalline particles of dicumarol and salicylic acid and 
their proton spin-lattice relaxation time (1H T1) was shown to exist; however, it did not follow 
the theoretical spin diffusion description and as a result a model was proposed.  
The potential implications of the findings presented here include the ability to evaluate 
the particle size distribution of crystalline powders using SSNMR. Significantly different particle 
sizes would be expected to have different 1H T1 times that can be detected within the powders. 
Moreover, since SSNMR can be used to characterize APIs in the presence of the excipients in a 
formulation, such evaluation of the polydispersity of powders could be conducted on formulated 
drug products during drug development. The next chapter presents the characterization of the 
particle size distribution of crystalline powders of dicumarol by SSNMR. 
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Figure 5.11 Proposed model; the markers represent the data presented earlier in this chapter, 
while the lines represent the proposed model 
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The ability to characterize the effect of tableting on the particle size of crystalline APIs 
and excipients by SSNMR is another ramification of the conclusions drawn here. Depending on 
the magnitude of the reduction in 1H T1 times observed upon tableting, if any, conclusions could 
be drawn on the impact of the compaction process on the particle size of the API or excipients. 
An investigation of the effect of compression forces on 1H T1 times will also be presented in the 
next chapter.  
Finally, another possible implication of the results presented here is the ability to assess 
the relative amount of crystal defects present in a given crystalline material. If the decrease in 1H 
T1 time upon milling a crystalline solid is larger than expected for the particle size obtained, this 
could indicate a large density of defects, which in turn could lead to a reduction in chemical 
stability. That is because crystal defects are believed to be the starting points of chemical 
reactions in the solid state. An example of the potential of SSNMR 1H T1 time measurements to 
be indicators of the chemical stability of crystalline APIs is presented in Chapter 7.  
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Chapter 6                                                                                        
Characterization of the polydispersity of powders and tablets using Solid-
State NMR Spectroscopy 
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6.1 Introduction 
In the previous chapter, it was shown that the particle size of crystalline dicumarol and 
salicylic acid could be quantitatively correlated to the SSNMR proton spin-lattice relaxation (1H 
T1) of the materials. In this chapter, the particle size distribution of crystalline dicumarol in 
powders, modeled by physical mixtures of crystalline samples of different particle sizes, is 
characterized using SSNMR proton spin-lattice relaxation time (1H T1) measurements, and the 
results are compared to laser diffraction. The impact of compaction forces on the particle-size 
distribution of salicylic acid in formulated tablets is also characterized using SSNMR and these 
results are then correlated to the dissolution profile of the API.  
6.1.1 Relevance of polydispersity in pharmaceuticals 
The particle size distribution, or polydispersity, of crystalline solid pharmaceuticals is an 
important property to characterize because it impacts the flow of the powder during 
manufacturing and the dose uniformity of the final drug product 1-3. Highly polydisperse powders 
composed of larger and smaller particles are more likely to segregate during mixing. This results 
in a lack of dose uniformity in the final formulated drug product. The polydispersity of a material 
could also affect its ability to be made into a tablet 4. Finally, the dissolution profile of a solid 
drug product can be impacted by the polydispersity of the particles in the powder as well. 
Smaller size particles are known to have a faster dissolution rate than larger particles, as 
described by the Noyes-Whitney equation: 
!"
!"
= !"(!!!!)
!
          (6.1) 
where dS/dt is the dissolution rate, D is the diffusion coefficient, A is the surface area, Cs is the 
concentration of the solid in the diffusion layer h immediately surrounding the drug particle, and 
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C is the concentration of the solid in the bulk medium. A powder composed of a very broad 
distribution of particles may not have a uniform dissolution profile, which might be detrimental 
to the bioavailability of the material. Conversely, a mixture of particles of different sizes could 
be used as a controlled-release drug delivery approach 5. Polydispersity is generally assessed 
using laser diffraction; however, in samples composed of a mixture of materials, such as 
pharmaceutical formulations, it is not possible to obtain polydispersity information for a single 
component of the mixture by laser diffraction. Such information might be needed should the 
formulation not perform as expected. 
6.2 Materials and Methods 
6.2.1 Sample preparation 
Cryogrinding 
After a 15 min precooling period, about 1.5 g of dicumarol was cryoground with alternating 
cycles of 2 min of cooling and 2 min of grinding (SPEX SamplePrep 6770 Freezer/Mill, 
SamplePrep, Inc., Metuchen, NJ). The rate of grinding was 10 counts per second. Total grinding 
times were 4 and 10 min. 
 
Preparation of physical mixtures. 
Two and three-component physical mixtures of cryoground dicumarol and as-received dicumarol 
were prepared. Each of the components of the physical mixtures were weighed individually and 
then mixed gently with a spatula.  The resulting mixture was then packed in a rotor. 
 
Preparation of salicylic acid tablets.  
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The salicylic acid tablets were prepared in the laboratory of Dr. Gregory Amidon at the 
University of Michigan (Ann Arbor, MI). They were composed of sieved salicylic acid (125-300 
µm) (50%) (125-300 µm), lactose monohydrate tabletose 80 (24.5%), microcrystalline cellulose 
(MCC) (24.5%), and magnesium stearate (1%) or sieved salicylic acid (50%) (125-300 µm), 
dicalcium phosphate (29.4%), microcrystalline cellulose (MCC) (19.6%), and magnesium 
stearate (1%). First, the excipients were blended together and then the API was added. The 
compaction forces used to prepare the tablets were varied resulting in tablets with different solid 
fractions. The solid fraction is equivalent to the density of the tablets. The diameter of all the 
tablets was approximately 5.6 mm. 
6.2.2 Sample characterization 
Differential Scanning Calorimetry (DSC) 
Small amounts of sample (1-4 mg) were weighed in a standard, hermetic or T-Zero normal TA 
aluminum pan. Samples were heated from -10ºC to 300ºC using a 10ºC/min ramp (DSC Q2000, 
TA Instruments, New Castle, DE).  
 
Solid-state NMR (SSNMR) 
13C SSNMR data were collected using a Tecmag Apollo (Tecmag, Inc., Houston, TX) 
spectrometer operating at a 13C frequency of ~300 MHz 1H frequency. The samples were packed 
in 7 mm zirconia rotors (Revolution NMR, Fort Collins, CO). A 2-module homebuilt probe was 
used. 3-methylglutaric acid (MGA) was used as an external standard, with the methyl peak 
referenced at 18.84 ppm 6. All spectra were acquired using ramp cross polarization and magic 
angle spinning (CP/MAS) 7-9.  A SPINAL-64 decoupling pulse sequence was used, and the 
spinning side bands were suppressed using total sideband suppression (TOSS). The acquisition 
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length was 2048 points for all salicylic acid samples and 1024 points for all dicumarol samples. 
The contact time employed was 1 ms for both compounds. Proton relaxation time values, 1H T1, 
were measured via saturation recovery.  
 
Fitting of 1H T1 data 
The peaks in the SSNMR spectra obtained during the saturation recovery experiment were 
integrated in the Tecmag NMR software (Tecmag, Inc., Houston, TX) and exported, along with 
the corresponding tau time interval values used during the saturation recovery NMR experiment. 
Using KaleidaGraph (Synergy Software, version 4.1), the peak areas were plotted against the tau 
values and fitted to a curve using the known exponential equation for the 1H T1 relaxation: 
!"#$%&'() = !! 1− !
! !!!(!)  (6.2). 
 The m1 coefficient and the 1H T1 are obtained from the fit.  
 
Laser diffraction 
Laser diffraction measurements were performed by Dr. Joseph Lubach at Genentech. A Malvern 
2000 Mastersizer was used. The powders were suspended in hexane and sonicated for 2 min in 
the measuring chamber before each measurement. The refractive index of dicumarol was 
calculated using the ACD Labs software. 
 
Dissolution 
Dissolution profiles for salicylic acid powder and formulated tablets were obtained using a 
MicroDiss apparatus (pIon, Billerica, MA). High purity water was used as the dissolution 
medium. The API concentration was kept at approximately 0.2 mg/mL and the volume of water 
	  
 146 
used was adjusted accordingly depending on the amount of API initially present. UV detection 
was over the range 260-340 nm. The dissolution profile of two tablets of each solid fraction was 
obtained and the average was used to construct the plots. 
6.3 Results and Discussion 
6.3.1 Dicumarol 
6.3.1.1 Effect of grinding on physical state and relaxation times of dicumarol 
Figure 6.1 is an overlay of the DSC thermograms of as-received, 4 min, and 10 min 
cryoground dicumarol. An endotherm indicative of the melting of dicumarol around 290 ºC is the 
only thermal event present in the three thermograms. There are no events below 290 ºC. The 
melting endotherm of the 10 min cryoground dicumarol is slightly broader than the endotherm of 
the other two samples, possibly due to poor thermal contact between the samples and the pan or 
particle size effects. Regardless, the DSC results indicate that dicumarol remained crystalline 
upon being milled. The physical state of the samples was also characterized by SSNMR. Figure 
6.2 shows the 13C SSNMR spectra of dicumarol as received and dicumarol cryoground for 4 and 
10 min. The three spectra contain the same number of peaks at the same chemical shifts, 
indicating that no polymorphic conversion occurred upon milling. The linewidths of the peaks in 
the three spectra are also very similar, although the peaks of the cryoground samples are slightly 
broader than the as-received material, as shown by the loss of resolution of the split peak at 115 
ppm.  
The 1H T1 time of dicumarol cryoground for 4 min was 13 s, and the 1H T1 time of the 10 
min cryoground material was 8 s. Both of these relaxation times are significantly shorter than the 
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Figure 6.1. DSC thermograms of as received, 4 min cryoground and 10 min cryoground 
dicumarol 
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Figure 6.2. 13C CP/MAS spectra of a. as received dicumarol; b. dicumarol cryoground for 4 min; 
c. dicumarol cryoground for 10 min
a 
b 
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1H T1 of the as-received material (1500 s); this was expected since grinding decreased the size of 
the particles, and it was shown in the previous chapter that the 1H T1 time of crystalline 
dicumarol decreases with particle size. The cryoground samples and the as-received dicumarol 
were used to prepare physical mixtures that were used as a model to study the 1H T1 relaxation 
behavior of highly heterogeneous crystalline powders and determine if the amount of each 
component of the mixture can be quantified by SSNMR.  
6.3.1.2 Characterization of 2-component physical mixtures of crystalline dicumarol by SSNMR 
relaxation measurements 
Five physical mixtures of as-received and 10 min cryoground dicumarol were prepared 
with ratios ranging from 10:90 to 90:10 (as received: cryoground w/w) (Table 6.1). As discussed 
in the previous section, both the as-received and the cryoground dicumarol are crystalline, and 
mixing them in a physical mixture was not expected to alter their physical state, as confirmed by 
the 13C SSNMR spectrum of the physical mixtures seen in Figure 6.3. Although the SSNMR 
spectra of all the mixtures are identical to each other and to the spectrum of as-received 
dicumarol, the relaxation times of the components of the mixtures are expected to be maintained 
in a physical mixture. This means that, unlike the individual pure materials, the relaxation 
behavior of the physical mixture will be best described with a bi-exponential equation, where 
each of the exponential term describes the relaxation of one of the components in the mixture. 
The following equation is used to fit the 1H T1 relaxation data of the two-component physical 
mixtures.  
!"#$%&'() = !! 1− !
! !!!(!) +!! 1− !
! !!!(!)  (6.3) 
The m1 and m2 pre-exponential coefficients are then used to calculate the ratio of each of the 
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Table 6.1. Theoretical ratios of physical mixtures of as-received and 10 min cryoground 
dicumarol 
 
 
Sample Theoretical fraction (by weight) 
As-received 0.899 
10-min cryoground 0.101 
As-received 0.251 
10-min cryoground 0.749 
As-received 0.498 
10-min cryoground 0.502 
As-received 0.751 
10-min cryoground 0.249 
As-received 0.102 
10-min cryoground 0.898 
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Figure 6.3 13C SSNMR spectra of a. physical mixture of as-received and 10 min cryoground 
dicumarol; 25:75  as-received:10 min cryoground dicumarol; b. as received dicumarol 
 
 
 
 
 
 
 
 
 
 
 
 
a 
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components in the mixture using the following equations.  
1 = !!
!!!!!
 (6.4)  
    
              2 = !!
!!!!!
 (6.5) 
The physical mixtures were prepared with two components whose individual 1H T1 times 
were known, and therefore there are two options for fitting the data. In method 1, the 1H T1 
curves could be fitted by setting the 1H T1 times in the equation to their known values and only 
letting the m1 and m2 coefficients be determined by the software fit. The 1H T1 time of as-
received dicumarol was set at 1500 s and that of the 10 min cryoground dicumarol was set to be 
8 s. The relative amounts of each material in the mixtures were calculated using equations 6.4 
and 6.5.  
In method 2, a value for the 1H T1 times is not set. In that case, the 1H T1 values obtained 
from the fit is used to determine which of the pre-exponential coefficients corresponds to the as-
received dicumarol and which one corresponds to the cryoground sample. Since the pure as-
received dicumarol has the longest 1H T1 time of the two components of the physical mixtures, 
the longer 1H T1 time was attributed to that material, and the shorter one to the cryoground 
sample. For example, when method 2 was used to fit the data of the 50:50 physical mixture, the 
following 1H T1 equation was obtained: 
!"#$%&'() = !! 1− !
! !!"""  ! +!! 1− !
! !!.!  !  (6.6) 
In equation 6.6, we attributed the 2000 s 1H T1 time to the as-received dicumarol and the 9.7 s 1H 
T1 time to the 10 min cryoground dicumarol; therefore, m1 corresponds to as-received dicumarol 
and m2 corresponds to the 10 min cryoground dicumarol.  
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The ratios of as-received and 10 min cryoground dicumarol in the physical mixtures were 
calculated using method 1 and method 2 and were compared to the theoretical ratios calculated 
from the weights of each of the materials in the mixtures. Table 6.2 summarizes the results. 
When using the first method, with the 1H T1 times set in the equation, the average difference 
between the theoretical and calculated ratios of as-received and cryoground dicumarol in the 
physical mixtures was 2.6% ± 2.1%. When the 1H T1 times are not set, as in method 2, the 
average difference between the theoretical and calculated ratios was 2.5% ± 3.1%. 
The results presented up to this point were calculated by fitting the entire curve obtained 
from plotting the integrated SSNMR peak areas versus the time τ to equation 6.3. Alternatively, 
the long and the short tau times can be treated as two separate data sets. Each curve is then fit to 
a mono-exponential T1 equation as defined in equation 6.2. At tau values longer than 50 s, the as-
received dicumarol is expected to be the only component of the physical mixture whose nuclei 
have not yet reached equilibrium. Due to its shorter 1H T1 time, the cryoground material has 
already returned to equilibrium at tau values greater than 50 s and its contribution to the amount 
of signal detected is expected to be constant at these tau values. Figure 6.4 shows the resulting 
curve for the 25: 75 as received: cryoground sample. Since only the longer tau values are used, 
the y-intercept of the curve is not zero or approaching zero. Instead, that value corresponds to the 
amount of cryoground sample present in the mixture and was used to calculate the ratios of the 
components of the mixture using equations 6.4 and 6.5. 
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Table 6.2. Ratios of physical mixtures of as-received and 10 min cryoground dicumarol- 
obtained with and without set 1H T1 times- Method 1 and method 2, respectively 
 
 
Sample Theoretical fraction 
Method 1 Method 2 1H T1 
(Method 2) Calculated 
fraction Δ 
Calculated 
fraction Δ 
As-received 0.899 0.843 
0.056 
0.819 
0.079 
1700s 
10-min cryo 0.101 0.157 0.181 5.2s 
As-received 0.751 0.743 
0.008 
0.745 
0.006 
1800s 
10-min cryo 0.249 0.257 0.255 11s 
As-received 0.498 0.460 
0.038 
0.471 
0.027 
2000s 
10-min cryo 0.502 0.540 0.529 9.7s 
As-received 0.251 0.243 
0.008 
0.253 
0.002 
1900s 
10-min cryo 0.749 0.757 0.747 7.0s 
As-received 0.102 0.123 
0.021 
0.114 
0.013 
890s 
10-min cryo 0.898 0.877 0.886 8.7s 
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Figure 6.4 Curve of integrated peak areas versus tau values for the 25:75 as-received:10 min 
cryoground physical mixture using only the longer tau values (> 50 s) to construct the plot and 
perform the fitting. 
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Once again, the fitting could be performed using either method 1 or method 2, in which the 1H T1 
times are specified or allowed to vary, specifically. The results are shown in Table 6.3. The 
average difference between the theoretical and calculated ratios was 2.7% ± 2.0% using method 
1, and 3.1% ± 1.7% using method 2. The largest differences between the theoretical and 
calculated ratios were observed with the 50:50 physical mixture. These results are comparable to 
the ones obtained when the tau values were not treated as separate data sets.  
The mixtures were only prepared once, therefore no standard deviation could be 
calculated. However, we can propose a few explanations for the difference observed between the 
calculated and the theoretical ratios. The first reason might be the quality of the fit, and the 
accuracy of the coefficients obtained from the fit. The Kaleidagraph software was used to fit the 
1H T1 data obtained experimentally by SSNMR to equation 6.3, and the R2 value obtained was 
used as an indicator of the quality of the fit; for all the mixtures, the R2 values were close to 1 
(>0.9). Therefore, the fit quality is likely not to blame. It is also possible that the weight-based 
theoretical ratios do not actually reflect the exact composition of the physical mixtures. This 
would be the case if the two powders were not homogeneously mixed before being packed in the 
rotor, and a small amount of powder was left on the weigh paper and did not get transferred to 
the rotor. Increasing the number of scans used to acquire the data, could also provide even better 
data through improving the signal to noise ratio of the spectra, as well as additional tau values. 
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Table 6.3. Calculated ratios and 1H T1 times of physical mixtures of as-received and 10 min 
cryoground dicumarol 
 
 
Sample Theoretical fraction 
Method 1 Method 2 1H T1 
(Method 2) Calculated 
fraction Δ 
Calculated 
fraction Δ 
As-received 0.899 0.886 0.013 
0.865 
0.034 
1900s 
10-min cryo 0.101 0.114 0.135 - 
As-received 0.751 0.717 0.034 0.710 0.041 
1800s 
10-min cryo 0.249 0.283 0.290 - 
As-received 0.498 0.441 0.057 
0.446 
0.052 
2000s 
10-min cryo 0.502 0.559 0.554 - 
As-received 0.251 0.243 
0.022 
0.234 
0.017 
2000s 
10-min cryo 0.749 0.757 0.766 - 
As-received 0.102 0.093 0.008 0.092 0.010 
1100s 
10-min cryo 0.898 0.907 0.908 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
 158 
6.3.1.3 Differences in 1H T1 times between pure materials and materials in the physical mixtures 
When using method 2, the calculated 1H T1 times of as-received and ground dicumarol in 
the physical mixtures were used to identify the pre-exponential coefficient that corresponded to 
each of the components in the mixture. However, the 1H T1 times of the components in the 
mixture did not always exactly match the 1H T1 times of the pure materials, though the two 
values were close. The 1H T1 values are summarized in Table 6.2 and 6.3. In all physical 
mixtures containing 25% of more of as as-received dicumarol, the 1H T1 of as-received 
dicumarol was longer than the one obtained with the pure material, with values ranging from 
1700 s to 1900 s; the 1H T1 time of the pure as-received dicumarol was 1500 s. In the mixture 
containing 10% as-received dicumarol, the 1H T1 time of this component were 890 s and 1100s. 
These differences in 1H T1 between the pure material and the material in the presence of another 
component were not expected. These differences suggest that it is more difficult to accurately 
determine the 1H T1 time of the minor component. Increasing the number of acquisitions 
collected during the proton-spin lattice relaxation experiment could potentially allow us to obtain 
more accurate 1H T1 times for the minor component.  
6.3.1.4 Comparison to laser diffraction measurements 
Figures 6.5 and 6.6 show the particle size distribution obtained by laser diffraction of two 
physical mixtures containing 50% and 10% by weight of as-received dicumarol. The 50:50 
physical mixture shows a clear bimodal distribution, similar to two overlapping Gaussian 
distributions. The particles present in the sample range from approximately 0.3 µm to 79 µm in 
diameter, with maxima at about 1.7 and 17 µm. By looking at the graph, one can estimate that 
the two particle size distributions in the samples are present in approximately equal amounts 
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Figure 6.5 Particle size distribution obtained using laser diffraction of physical mixture of as-
received and 10 min cryoground dicumarol; 50:50 as-received:10 min cryoground  
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Figure 6.6. Particle size distribution using laser diffraction of physical mixture of as-received 
and 10 min cryoground dicumarol; 10:90  as-received:10 min cryoground  
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since the two distributions peak at approximately the same volume percentage. For the 10:90 
physical mixture containing 10 % of as-received material (shown in Figure 6.6), instead of the 
expected bimodal distribution, a tri-modal distribution was obtained. The large Gaussian 
distribution has a maximum at about 1.7 µm and the two smaller distributions have maxima at 
approximately 10 and 60 µm. Though a trimodal distribution was unexpected, the data clearly 
shows that the smaller range of particles constitutes the largest part of the sample. These results 
indicate that the particle size distribution data obtained by laser diffraction mostly agree with the 
theory and the SSNMR results. Furthermore, the 50:50 distribution looks similar to the laser 
diffraction data obtained for two samples, Lot C and Lot D of precipitated dicumarol (Figure 
5.4), prepared and characterized in the previous chapters. This supports the fact that the two 
distinct 1H T1 times obtained for these samples were due to a bimodal distribution in particle size.   
6.3.1.5 Characterization of 3-component physical mixtures of crystalline dicumarol by SSNMR 
relaxation measurements 
The two orders of magnitude difference between the 1H T1 time of as-received and 10 min 
cryoground dicumarol allowed us to distinguish and quantify them in the physical mixtures using 
SSNMR. In order to study a more complex case, and one in which the components of the 
mixture have 1H T1 times that are closer in magnitude, physical mixtures containing various 
ratios of as-received dicumarol, 4 min cryoground dicumarol, and 10 min cryoground dicumarol 
were prepared and characterized. Table 6.4 summarizes the composition of the mixtures 
prepared. 
The 1H T1 time of the cryoground dicumarol samples are 8 s for the 10 min cryoground 
material and 13 s for the 4 min cryoground dicumarol. Because there are three different materials 
with different relaxation rates in the physical mixtures, the equation used to fit the spin lattice 
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Table 6.4 Theoretical ratios of physical mixtures of as-received, 4 min cryoground and 10 min 
cryoground dicumarol 
 
 
Sample Theoretical fraction (by weight) 
As-received 0.50 
4 min cryoground 0.25 
10-min cryoground 0.25 
As-received 0.10 
4 min cryoground 0.60 
10-min cryoground 0.30 
As-received 0.40 
4 min cryoground 0.10 
10-min cryoground 0.50 
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relaxation data contains three exponential terms.  
!"#$%&'() = !! 1− !
! !!!(!) +!! 1− !
! !!!(!) +!! 1− !
! !!!(!)  (6.7) 
Similarly to what was described with the bi-exponential equation, the pre-exponential 
coefficients m1, m2, and m3 can be used to calculate the ratio of each of the components in the 
mixture with the following equations. 
   1 = !!
!!!!!!!!
            (6.8) 
 
   2 = !!
!!!!!!!!
            (6.9) 
 
   3 = !!
!!!!!!!!
            (6.10) 
Again, the data could be fitted two different ways: by setting a value for the 1H T1 times (method 
1), or letting that value vary (method 2). However, when a value was set for 1H T1 times, the pre-
exponential coefficients observed for the 4 min cryoground sample were negative. This is 
physically impossible therefore only method 1 was used and the longest 1H T1 time was 
attributed to the as-received dicumarol and the shortest one to the 10 min cryoground material 
since the 1H T1 times of the pure samples follow that trend. Table 6.5 summarizes the theoretical 
and calculated ratios. Both ratios agreed within 10% or less of each other only for as-received 
dicumarol. The calculated ratios of each of the cryoground materials in the physical mixtures 
were significantly over- or underestimated. In particular, the ratios of the cryoground materials 
calculated using the NMR coefficients in the physical mixture composed of 40, 50 and 10% of 
as-received, 10 min cryoground, and 4 min cryoground dicumarol, respectively, differed by more 
than 35% from the theoretical ones. We believe that the poor agreement between the two values 
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Table 6.5. Ratios and 1H T1 times of physical mixtures of as-received, 4 min cryoground and 10 
min cryoground dicumarol 
 
Sample Theoretical fraction 
Calculated 
fraction 
Absolute 
difference 
1H T1 
As-received 0.50 0.450 0.052 2100s 
4 min cryo 0.25 0.189 0.059 53s 
10-min cryo 0.25 0.361 0.112 6.9s 
As-received 0.10 0.105 0.001 1600s 
4 min cryo 0.60 0.734 0.140 15s 
10-min cryo 0.30 0.161 0.141 5s 
As-received 0.40 0.414 0.013 2700s 
4 min cryo 0.10 0.470 0.365 14s 
10-min cryo 0.50 0.116 0.379 4s 
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is due to the assumption that we made earlier that the shortest 1H T1 time obtained when fitting 
the data of the physical mixture is from the 10-min cryoground dicumarol. When that assumption 
is not made, and the pre-exponential m coefficients used to calculate the relative amounts of 4 
min and 10 min cryoground dicumarol in the mixture are switched, there is better agreement 
between the theoretical and the calculated ratios. This result suggests that it is difficult to 
distinguish components of a highly heterogeneous powder whose 1H T1 times are very close to 
each other. Furthermore, the 1H T1 time of the 4 min cryoground dicumarol in the mixtures 
ranged from 14 s to 53 s, while the 1H T1 time of the 10 min cryoground material ranged from 4 s 
to 6.9 s. Those values are unexpectedly very far from the 1H T1 values of 4 min and 10 min 
cryoground dicumarol alone: 13 s and 8 s, respectively.  
In order to determine if the agreement between theoretical and calculated numbers would 
improve when the cryoground samples were treated as one material, a bi-exponential equation 
was used to fit the 1H T1 data. Again, either method 1 or method 2 could be used to fit the data, 
and the results obtained with both methods are presented in Table 6.6. The calculated amounts of 
total cryoground material in the physical mixtures are within 1-3 % of the theoretical amount. 
While SSNMR can distinguish between relaxation time that differ by one order of magnitude or 
more, this result demonstrates that SSNMR cannot differentiate between materials with very 
similar relaxation behavior.  
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Table 6.6. Ratios and 1H T1 times of physical mixtures of as-received, 4 min cryoground and 10 
min cryoground dicumarol treated as 2-component physical mixtures, analyzed with or without 
setting a value for the 1H T1 time of as-received dicumarol- Method 1 and method 2, respectively 
 
Sample Theoretical fraction 
Method 1 Method 2 1H T1 
(Method 2) Calculated 
fraction Δ 
Calculated 
fraction Δ 
As-received 0.502 0.465 0.037 0.489 0.013 
1500s 
4+10-min cryo 0.498 0.535 0.511 - 
As-received 0.104 0.113 0.009 0.113 0.009 
1010s 
4+10-min cryo 0.896 0.887 0.887 - 
As-received 0.401 0.362 0.039 0.428 0.027 
2600s 
4+10-min cryo 0.599 0.638 0.572 - 
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6.3.2 Salicylic acid formulations 
Tableting is a commonly used manufacturing process that can affect the polydispersity of 
solid pharmaceuticals. While the previous sections focused on characterizing the polydispersity 
of dicumarol in powders, in the following sections the effect of compaction forces on the 
poydispersity of another API, salicylic acid, in formulated tablets will be studied using SSNMR 
1H T1 times measurements and the results will be correlated to the dissolution rate of the 
material.   
6.3.2.1 Effect of compaction force and excipient type on the 1H T1 times of salicylic acid in 
formulated tablets 
Two formulations were tableted using different compaction forces and the 1H T1 time of 
salicylic acid in the tablets was obtained. Table 6.7 summarizes the compaction forces used for 
each formulation and the solid fraction, or density, of the resulting tablets. Formulation A was 
composed of sieved salicylic acid (125-300 µm), lactose monohydrate, MCC, and magnesium 
stearate, and Formulation B was composed of sieved salicylic acid (125-300 µm), dicalcium 
phosphate, MCC, and magnesium stearate. The 1H T1 time of the 125-300 µm sieved fraction of 
salicylic acid is 3900 s. The spin-lattice relaxation behavior of as-received α-lactose 
monohydrate tabletose was best modeled with two 1H T1 times: 60 s and 200 s, and the ratios of 
material at the origin of each 1H T1 were 63% and 37 %, respectively. However, after blending 
with the other excipients, only one 1H T1 time was obtained for lactose: 89 s. This suggests that 
blending increased the homogeneity of the lactose. In order to measure the 1H T1 times of 
salicylic acid and lactose monohydrate in the tablets, we first identified the peaks in the spectra 
that could be integrated to perform the 1H T1 time measurements. 
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Table 6.7. Compression forces used to prepare the salicylic acid tablets from a. Formulation A; 
b. Formulation B 
 
a. 
Tablet set Punch applied force (lbs) Solid Fraction 
1 350 0.81 
2 550 0.86 
3 1000 0.90 
4 2500 0.93 
 
b. 
Table set Punch applied force (lbs) Solid Fraction 
1 350 0.79 
2 1000 0.86 
3 2500 0.91 
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Figure 6.7 shows the 13C SSNMR spectra of as-received lactose monohydrate and 
microcrystalline cellulose (MCC). A 13C SSNMR spectrum of dicalcium phosphate cannot be 
obtained because that material does not contain any 13C. Lactose is crystalline and is present as 
its α polymorph; this polymorphic identification can be made based on work previously done on 
lactose in our laboratory 10. MCC contains broad peaks indicating that it is amorphous. The 
peaks of both of these excipients are contained within the 112-50 ppm region of the spectrum.  
Figure 6.8 shows the 13C SSNMR spectra of as-received salicylic acid and representative 
spectra of salicylic acid tablets prepared from Formulation A and Formulation B. The peaks 
below 112 ppm in Figure 6.8b are from MCC, and in Figure 6.8c they are from both MCC and α-
lactose monohydrate. Lactose remained crystalline after blending and compaction, as evidenced 
by the sharp peak at 92 ppm in the 13C SSNMR spectrum obtained from the tablets. The peaks 
between 200 and 112 ppm belong to salicylic acid. They are sharp and narrow indicating that 
processing did not change the crystalline state of salicylic acid either. The salicylic acid peaks 
between 200 and 112 ppm and the lactose peak at about 92 ppm were used to obtain the 1H T1 
times of the two materials.  
The 1H T1 times of salicylic acid and lactose monohydrate prepared from Formulation A 
are presented in Tables 6.8a and 6.8b. The 1H T1 data for both salicylic acid and lactose in the 
tablets prepared from Formulation A were first fitted with a mono-exponential equation (Table 
6.7a). However, the spin-lattice relaxation curves of salicylic acid in the Formulation A tablets 
prepared with compaction forces of 550 and 1000 lbs, and of lactose in the tablets prepared with 
compaction forces of 550, 1000 and 2500 lbs were found to be best fitted using two distinct 1H 
T1 times (Table 6.7b). When the other sets of tablets were fitted with bi-exponential equations the 
1H T1 times obtained had large errors associated with them. The tablets better described with two 
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Figure 6.7. 13C CP/MAS spectrum of a. microcrystalline cellulose (MCC); b. α-lactose 
monohydrate tabletose 80  
 
 
 
 
b 
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Figure 6.8 13C SSNMR spectra of a. as-received salicylic acid b. representative tablet of 
salicylic acid with dicalcium phosphate c. representative tablet of salicylic acid with lactose 
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Table 6.8 1H T1 times of lactose and salicylic acid in the Formulation A tablets obtained using 
mono-exponential (a) and bi-exponential fits (b); the errors indicated are the errors of the fit. The 
percentages in parenthesis indicate the amount of material at the origin of that 1H T1 time.  
 
 
a. 
 
Tablet 
set 
Solid 
Fraction 
Punch applied force 
(lbs) Salicylic acid 
1H T1 Lactose 1H T1 
  0 3900 s 89 s 
1 0.81 350 2200 s ± 370 83 s  ± 5 
2 0.86 550 2100 s ± 350 73 s ± 5 
3 0.90 1000 2000 s ± 290 79 s ± 7 
4 0.93 2500 1400 s ± 126 51 s ± 6 
 
 
b. 
 
 
 
 
 
 
 
 
Tablet 
set 
Solid 
Fraction 
Punch applied 
force (lbs) Salicylic acid 
1H T1 Lactose 1H T1 
  0 - - - - 
1 0.81 350 - - - - 
2 0.86 550 560 s ± 180 (41%) 
5300 s ± 1900 
(59%) 
13 s ± 8 
(19%) 
93 s ± 14 
(81%) 
3 0.90 1000 500 s ± 240 (36 %) 
3500 s ± 1100 
(64%) 
16 s ± 6 
(31%) 
120 s ± 26 
(69%) 
4 0.93 2500 - - 5 s ± 2 (27%) 
68 s ± 6  
(73%) 
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1H T1 times may contain both smaller and larger particles that differ significantly in their size. 
The smaller particles would likely result from larger chunks fragmenting during the tableting 
process. It is not possible to determine using the SSNMR data if segregated domains of each type 
of particle exist in the tablets or if they are intimately mixed. A large error is associated with the 
1H T1 times of salicylic acid resulting from 2-component fits, rendering it difficult to establish a 
trend between the compaction forces and the 1H T1 times using that set of data. This is somewhat 
not surprising since it was shown earlier, with the dicumarol physical mixtures (§6.3.1.3), that it 
could be difficult to obtain accurate 1H T1 times for the components of heterogeneous materials: 
the 1H T1 times of as-received and cryoground dicumarol in the physical mixture were not always 
the expected values However, some observations on the changes in 1H T1 times with compaction 
forces can be made. 
The 1H T1 times of lactose monohydrate and salicylic acid in the tablets are shorter than 
the 1H T1 times of the materials before tableting. The shortest 1H T1 time obtained for salicylic 
acid was 1400 s, and it was 51 s for lactose monohydrate compared to 3900 s and 89 s for the 
untableted materials. Generally, the 1H T1 times of both materials decreased with increasing 
compaction forces and increasing solid fraction; however, the lactose in the set of tablets # 3 
seems to be an outlier to this trend: its 1H T1 time (79 s) is longer than the 1H T1 times of lactose 
in tablet set #4 (51s). 
Salicylic acid in the tablets prepared using Formulation B were best fitted using two 
distinct 1H T1 times; the values obtained are presented in Table 6.9. Again, the fact that two 1H T1 
times were needed to accurately describe the spin-lattice relaxation of the tablets suggests that 
smaller and larger particle size distributions are present in the tablets. Similarly to the tablets  
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Table 6.9 1H T1 times of salicylic acid in the Formulation B tablets. The percentages in 
parenthesis indicate the amount of material at the origin of that 1H T1 time calculated using 
equations 6.4 and 6.5. 
 
 
Table set Solid Fraction Punch applied force (lbs) Salicylic acid 
1H T1 
1 0.79 350 760s ± 800 (21%) 3600s ± 1300 (79%) 
2 0.86 1000 390s ± 150 (39%) 3800s ± 1300 (69%) 
3 0.91 2500 260s ± 74 (28%) 2200s ± 240 (72%) 
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prepared using Formulation A, higher compaction forces were associated with shorter 1H T1 
times. For sets of tablets 1 and 2, the longer 1H T1 time of the two 1H T1 times detected was 
approximately the same as the 3900 s 1H T1 time of untableted sieved salicylic acid. The long 1H 
T1 time of the tablets prepared with compaction forces of 2500 lbs was 2200s. The shorter 1H T1 
times were more significantly different, and the tablets prepared with the stronger compaction 
force had the shortest 1H T1 time overall (260 s). 
6.3.2.2 Effect of compaction forces and excipient type on the dissolution rate of salicylic acid in 
tablets 
Figure 6.9a is an overlay of the dissolution curves of the 125-300 µm sieved salicylic acid 
fraction and tablets of salicylic acid prepared from Formulation A, the lactose-containing 
formulation. The relative amount of salicylic acid dissolved is plotted versus the time in seconds. 
The set 1 of Formulation A tablets (350 lbs) were damaged during shipping and even more while 
in the spinning rotor during the SSNMR experiment; as a result, no dissolution data was obtained 
on these tablets. The sieved salicylic acid has the fastest dissolution rate of all the materials, and 
approximately 90 % of the salicylic acid was dissolved after 500 s. About 92 % of the salicylic 
acid initially present in the tablets was dissolved after 1920 s, at the end of the dissolution study. 
The shape of the dissolution curves of all the tablets is sinusoidal indicating that there is a short 
lag before salicylic acid starts dissolving into solution. That lag time lasted approximately 70- 80 
s for the tablets and is believed to be the time that it takes the tablets to disintegrate. Between 80 
and 500 s, the dissolution rate of salicylic in the tablets is fastest for tablets set 4 (solid fraction 
of 0.93) and slowest for the tablet set 3 (solid fraction equal to 0.90). The dissolution rate of 
salicylic acid from the tablets in set 2 (solid fraction of 0.86) is between these two although it is 
closer to that of the tablets with a solid fraction of 0.93. For both the tablet set 4 and tablet set 2,  
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Figure 6.9. Dissolution profile of salicylic acid in tablets; n=2. The error bars represent the 
deviation from the mean
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approxiately 90% of the salicylic acid initially present in the tablets was dissolved after 800 s. 
After that point the curves start to plateau out and the final amount of salicylic acid present 
insolution after 2100 s is about 95% of the nominal amount present initially. For the tablets with 
a 0.90 solid fraction, only about 85% of the salicylic acid initially present in the tablets was in 
solution after about 800 s. The dissolution curve begins to plateau out near 1100 s and about 90% 
of the relative amount of salicylic acid initially present in the tablets is in solution at the end of 
the dissolution study. 
Figure 6.9b in an overlay of the dissolution profile of sieved salicylic acid and the 
salicylic acid tablets prepared using dicalcium phosphate (Formulation B). No lag time is present 
in the dissolution curves of the tablets prepared with the lowest compaction forces, tablets set 1 
and 2 (350 and 1000 lbs), while a short lag time of ~40s exists with the tablets prepared with the 
strongest compaction forces (tablet set 3) (2500 lbs). After that time the three sets of tablets have 
similar dissolution profiles and follow the same type of dissolution profile as the free powder.  
During the dissolution experiments it was also noted that the tablets containing dicalcium 
phosphate almost immediately disintegrated once placed in water, with the exception of the 
tablet prepared with the strongest compaction forces. This observation is consistent with the 
explanation that the lag time observed with the tablets containing lactose is due to the slower 
disintegration of the tablets.  Very little difference exists between the different tablets in terms of 
amounts of salicylic acid dissolved at the end of the dissolution study. However, the dissolution 
rate of salicylic acid was slightly faster in the tablet set 2  (solid fraction of 0.86). The percentage 
of salicylic acid present in solution after 500 s for the tablets sets 1 and 2 (solid fraction of 0.79 
and 0.86) was approximately 80% and 88%, respectively. It was also about 80 % for tablet set 3.  
The final relative amounts of salicylic acid in solution at the end of the study were only slightly 
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higher than those values. For both formulations, a larger tablet solid fraction was associated with 
faster dissolution of salicylic acid. Only the tablets of lactose and salicylic acid with a solid 
fraction of 0.90 did not follow this trend.  An explanation for this was not immediately apparent. 
6.3.2.3 Relationship between dissolution profile and 1H T1 times of salicylic acid and lactose 
monohydrate in formulated tablets 
For all the tablets, the 1H T1 time of salicylic acid and the dissolution rate seemed to 
correlate: a shorter 1H T1 time was associated with a faster dissolution rate. This was more easily 
seen with the tablets prepared with lactose (Formulation A), since the tablets containing lactose 
all have very similar dissolution profiles. In Chapter 5, it was shown that shorter 1H T1 times 
were associated with smaller particles, and it is possible that compaction caused some of the 
particles of salicylic acid to fragment into smaller particles with stronger compaction forces 
generating smaller particles. It is interesting to note that the set number 3 of tablets containing 
lactose did not follow the trends associated with increasing compaction forces causing either a 
decrease in 1H T1 times of lactose monohydrate or faster dissolution rates. The 1H T1 time of 
lactose in the tablet set 3 of Formulation A (1000 lbs compression forces, solid fraction of 0.90) 
was higher than the 1H T1 time of lactose in the tablet set 4; a value of about 60 s was expected 
and instead the 1H T1 time of lactose obtained is 120 s.  This indicates that the 1H T1 time of 
lactose, not of salicylic acid, could be used to predict the dissolution behavior of salicylic acid. 
Further supporting the significant influence of lactose monohydrate on the dissolution profile of 
the API is the fact that in the tablets where lactose is not present, the dissolution profile of 
salicylic acid closely mirrors the profile of the free powder. The differences in water solubility 
between MCC and lactose could help explain these observations. Lactose is soluble in water 
while MCC is not, as a result the presence of lactose would be expected to impact the dissolution 
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profile of salicylic acid from the tablet as it would be dissolving also. Conversely, MCC does not 
dissolve, hence the similarity between the dissolution profile of the salicylic acid in powder form 
and the salicylic acid in the MCC-containing tablets. 
These observations strongly suggest that lactose is a major factor in the dissolution 
behavior of tablets in solution and that 1H T1 times measurements could potentially be used to 
predict that behavior. However, more data on more samples is likely needed in order to be able 
to draw firmer conclusions.  
6.4 Conclusions 
The findings presented in this chapter indicate that highly polydisperse crystalline 
samples can be distinguished from homogeneous samples based on the number of 1H T1 times 
detected. The relative amount of each phase can also be quantified. The effect of compaction 
forces on the tablets homogeneity can also be assessed in the same way, and it was found that 
stronger compaction forces were associated with shorter 1H T1 times. Decreases in 1H T1 times 
after compaction have previously been observed with pure lactose monohydrate, however only 
one compaction force was studied 10. Here, the different compaction forces appear to have 
different effects on the formulated API as in addition to the reduction in 1H T1 time, some of 
them have generated materials whose spin lattice relaxation is best described using two 1H T1 
times. This suggests that these tablets contain both larger and smaller particles.  
Finally, a relationship between compaction forces, 1H T1 times and dissolution rate was 
found, and the influence of the excipients on the dissolution profile of the API was underlined. 
These results highlight the potential for 1H T1 times measurements of crystalline solid 
pharmaceuticals to be used for the prediction of physicochemical properties such as mixing level 
and dissolution rate.  
	  
	   180 
6.5 References 
1. Johnson MC 1972. Particle size distribution of the active ingredient for solid dosage 
forms of low dosage. Pharm Acta Helv  47(8):546-559. 
2. Swaminathan V, Kildsig D 2002. Polydisperse Powder Mixtures: Effect of Particle Size 
and Shape on Mixture Stability. Drug Development & Industrial Pharmacy  28(1):41-48. 
3. Yalkowsky SH, Bolton S 1990. Particle size and content uniformity. Pharm Res  
7(Copyright (C) 2012 U.S. National Library of Medicine.):962-966. 
4. Yajima T, Itai S, Hayashi H, Takayama K, Nagi T 1996. Optimization of size distribution 
of granules for tablet compression. Chem Pharm Bull  44(Copyright (C) 2012 American 
Chemical Society (ACS). All Rights Reserved.):1056-1060. 
5. Iacocca RG, Burcham CL, Hilden LR 2010. Particle engineering: A strategy for 
establishing drug substance physical property specifications during small molecule development. 
Journal of Pharmaceutical Sciences  99(1):51-75. 
6. Barich DH, Gorman EM, Zell MT, Munson EJ 2006. 3-Methylglutaric acid as a 13C 
solid-state NMR standard. Solid State Nuclear Magnetic Resonance  30(3-4):125-129. 
7. Pines A 1973. Proton-enhanced NMR of dilute spins in solids. J Chem Phys  59(2):569. 
8. Andrew ER, Bradbury A, Eades RG 1959. Removal of Dipolar Broadening of Nuclear 
Magnetic Resonance Spectra of Solids by Specimen Rotation. Nature  183(4678):1802-1803. 
9. Lowe IJ 1959. Free Induction Decays of Rotating Solids. Physical Review Letters  
2(7):285-287. 
10. Lubach JW, Xu D, Segmuller BE, Munson EJ 2007. Investigation of the effects of 
pharmaceutical processing upon solid-state NMR relaxation times and implications to solid-state 
formulation stability. Journal of Pharmaceutical Sciences  96(4):777-787. 
	  
	   181 
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Investigation of the effect of milling on gabapentin physical and chemical 
stability 
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7.1 Introduction 
The previous chapters focused on the correlation between the particle size of crystalline 
solids and their SSNMR proton-spin-lattice relaxation (1H T1) times using dicumarol and 
salicylic acid as model compounds. In Chapter 6, the ability to use 1H T1 times to determine the 
polydispersity of powders was shown, as well as the ability to predict the dissolution behavior of 
a tableted crystalline API. In this chapter, the correlation between the proton spin-lattice 
relaxation (1H T1) time, the amounts of defects present in a ground API, and the chemical 
stability of the material is demonstrated, thus highlighting further the relevance and utility of 
using 1H T1 times to characterize pharmaceutical solids.  
7.1.1 Chemical stability in solids 
The chemical stability of pharmaceutical solids is currently assessed and predicted by 
submitting the material to lengthy stability tests and using kinetic models to fit the data. 
However, solids do not behave as homogeneous systems, rendering their solid-state chemical 
kinetics difficult to predict, and extrapolations from the kinetic model to the actual stability of 
the material at ambient conditions difficult to make. One of the most common kinetic models is 
the Prout-Tompkins model. It was first proposed in 1944 to describe the thermal decomposition 
of crystals of potassium permanganate, and since then it has been widely applied to 
pharmaceutical systems 1,2. The Prout-Tompkins equation assumes that the rate of chemical 
degradation reaction is controlled by linearly growing nuclei that spread from the nucleation site 
through the crystal by branching. This makes the presence of nucleating sites a critical aspect of 
the solid-state reaction mechanism. Carstensen has extensively studied the kinetics of the solid-
state degradation of aspirin using a Prout-Tompkins model 3,4.  
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Changes in the chemical stability of solid pharmaceuticals can occur as a result of 
manufacturing processes such as milling 5-9. Previous studies in the Munson laboratory have 
investigated the correlation between the presence of crystal defects in milled aspirin, the 
chemical stability of the material, and its proton spin-lattice relaxation time 1H T1 10. In that 
study, aspirin was cryoground for up to 60 min and the 1H T1 times and 13C SSNMR spectra of 
the ground materials were collected. The 13C SSNMR spectra indicated that all the materials 
were still crystalline after grinding. However, a stability study of the ground materials revealed 
that 60 min of cryogrinding created a very unstable material that completely degraded to salicylic 
acid and acetic acid after 3 days under stability conditions (50% RH, 75ºC). That material also 
had the lowest 1H T1 time of all the aspirin samples. The aspirin sample that was ground for the 
shortest amount of time had the longest 1H T1 time and was the most chemically stable. It still 
contained more than 80% of aspirin after 3 days under stability conditions. This study 
highlighted the potential for 1H T1 times to serve as stability predictors of crystalline materials.  
In this chapter we extend the work of Lubach on aspirin to another API: gabapentin.  
7.1.2 Gabapentin as a model compound 
Gabapentin is an excellent model compound for this study because it has known chemical 
stability issues 11. It is known to degrade to a cyclic lactam via a dehydration reaction. Recently, 
Zong and coworkers investigated the effect of milling on both the physical and chemical stability 
of gabapentin 11. They milled Form II for 15-60 min and stored the samples at 50 ºC, at relative 
humidity values ranging from 5 to 80%. The chemical stability was assessed by the amount of 
gabapentin lactam formed. While milling did not cause any physical transformation, the amount 
of lactam formed increased with milling time. Moisture had an unusual stabilizing effect and 
prevented further degradation to the lactam. They concluded that while milling is known to 
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introduce lattice disorder, moisture may bring about recrystallization (“healing of the crystal 
defects”) and thereby stabilize the material.   
Gabapentin also has several known crystal forms that may impact its stability. Three 
polymorphic forms of gabapentin and a hydrate have been reported in the literature: Forms II, 
III, and IV are anhydrous forms, while Form I was later discovered to be a monohydrate 
therefore not an actual polymorph of the material 12,13. Form II is the most thermodynamically 
stable form under ambient conditions. Form III and Form IV are metastable, and the latter has 
not been well characterized. A number of groups have studied the interconversion of gabapentin 
crystalline forms as a result of milling and other stress factors such as heating 13-15. Fourier-
Transform Infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC), 
thermogravimetric analysis (TGA) and powder X-Ray diffraction (PXRD) were the techniques 
used to characterize gabapentin forms in all the reports. 
In this chapter, solid-state NMR (SSNMR), along with PXRD and DSC, were used to 
characterize the physical state of gabapentin, and SSNMR relaxation times were correlated to the 
propensity of gabapentin to chemically degrade to its lactam upon being milled.  
7.2 Materials and Methods 
Gabapentin (Form II) was obtained from Hangzhou Starshine Pharmaceutical Co. LTD 
(Hangzhou, China). Gabapentin lactam was purchased from Sigma Aldrich (St. Louis, MO). 
Because this work was a collaborative project performed in the context of NIPTE (National 
Institute for Pharmaceutical Technology and Education) some of the sample preparation and 
characterization was performed at the University of Minnesota or the University of Iowa. 
7.2.1 Sample preparation 
Preparation of Form III and Form I 
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Gabapentin Form I was prepared using the method of Ibers by dissolving 160 mg of 
gabapentin Form II in 1 mL of water, adding 3 mL of 2-propanol, and keeping it in the freezer 
for six days 16. The crystals were then harvested. Thermogravimetric analysis (TGA) of Form I 
revealed a weight loss of ~9%, close to the stoichiometric water content of 10% for the 
monohydrate. Gabapentin Form III was crystallized from a saturated 95% ethanol solution at 60 
ºC. The temperature was kept constant throughout the crystallization process. These samples and 
the milled samples were prepared at the University of Iowa. 
 
Spray-drying 
A 5% solution (w/w) of gabapentin in a solution of water: ethanol (1:2) was spray dried in a 
Buchi spray dryer. The inlet temperature was 60ºC, the aspiration rate was 100% of the pump 
capacity and the pump rate was 5% of the pump capacity. The spray drying was performed at the 
University of Minnesota in the laboratory of Dr. Suryanarayanan. 
 
Milling 
Gabapentin Form II was milled in a planeraty mill for 45 min with four hardened steel balls 
(Pulviserette 7, Planetary Micro Mill) 
7.2.2 Sample characterization 
Polarized Light Microscopy (PLM) 
Samples were imaged on a polarized light Olympus microscope (Center Valley, PA) under a 
20X objective.  
 
Powder X-Ray Diffraction 
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The diffraction patterns were collected using a wide angle X-ray diffractometer (model D5005, 
Bruker, Madison, WI) at ambient temperature. The instrument was operated in a step-scan mode, 
in 0.05º2θ steps, and counts were accumulated for 1.0 second at each step over the range of 5 to 
40°2θ. The PXRD patterns were obtained at the University of Minnesota in the laboratory of Dr. 
Suryanarayanan. 
 
High-Performance Liquid Chromatography (HPLC) 
A Thermo Spectrum HPLC System (P4000 pump, AS3000 auto injector, and UV 6000 LP 
photodiode array detection system) was used to quantify gabapentin and gabapentin lactam. The 
results are reported as a mole percentage (w/w) of total gabapentin (gabapentin + gabapentin 
lactam). The amount of gabapentin lactam generated during milling was determined from HPLC 
of samples before and after milling. A small amount of each of the gabapentin samples was 
stored at 50 ºC and 0% relative humidity for 24 hours and then subjected to HPLC. HPLC 
measurements on these samples were used to determine the amount of chemical degradation 
occurring upon thermal stress. The HPLC stability studies were performed in the laboratory of 
Dr. Kirsch at the University of Iowa. 
 
Solid State Nuclear Magnetic Resonance (SSNMR) Spectroscopy 
13C SSNMR spectra were collected using either a Chemagnetics CMX300 (Varian, Palo Alto, 
CA), a Bruker Avance 300 (Bruker, Billerica, MA) or a Tecmag Apollo (Tecmag, Inc., Houston, 
TX) spectrometer all operating at a 13C frequency of ~75 MHz.  Each sample was packed under 
ambient conditions in a 7 mm zirconia rotor (Revolution NMR, Fort Collins, CO).  3-
methylglutaric acid was used as an external standard, with methyl peak referenced to 18.84 ppm 
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17. All spectra were acquired using ramp cross polarization and magic angle spinning (CP/MAS) 
18-20.  A SPINAL-64 decoupling pulse sequence was used, and the spinning side bands were 
suppressed using total sideband suppression (TOSS). A contact time of 1 ms, MAS frequency of 
4.0 kHz and a 1H decoupling field of 70-80 kHz were used. Proton relaxation time values, 1H T1, 
were measured by saturation recovery. 
7.3 Results and discussion 
 Before studying the chemical degradation induced by milling of gabapentin Form II, all 
the known forms of gabapentin were first characterized. During the characterization process, one 
new form was identified.  
7.3.1 Gabapentin forms characterization by SSNMR 
Figure 7.1 shows the 13C SSNMR spectrum of Form II of gabapentin. The spectrum has 
one peak in the carbonyl region at 179 ppm, and eight peaks in the aliphatic region between 20 
and 60 ppm. The peak at 39 ppm is broadened due to coupling with 14N. This peak is useful for 
identifying different crystalline forms of gabapentin because of its distinctive line shape. The 
linewidths of the other peaks vary from 10-15 Hz. Because the carbonyl peak is separate from 
the aliphatic peaks, only the aliphatic region is shown in the spectra presented in the rest of this 
chapter.  
Figure 7.2 shows the aliphatic region of the 13C SSNMR spectra of the known crystalline 
forms of gabapentin that have been analyzed in our laboratory, as well as gabapentin lactam. In 
contrast to gabapentin Form II, the crystalline Forms I and III only have seven peaks in the 
aliphatic region of their spectra. This is likely due to overlapping peaks of two carbons between 
20-25 ppm, which results in a broader peak at 22 ppm for Form III and 22.5 ppm for Form I. In  
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Figure 7.1 13C CP/MAS SSNMR spectrum of gabapentin Form II and chemical structure of 
gabapentin 
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Figure 7.2 Aliphatic region of 13C CP/MAS SSNMR spectra of a. gabapentin Form II; b. 
gabapentin Form III; c. gabapentin Form I; d. gabapentin lactam 
(*) indicates the nitrogen-split peak. 
a	  
c	  
d	  
b	  
*	  
*	  
*	  
	  
 190 
Form III, the carbon peak that is broadened due to 14N coupling is located at 51 ppm. There is a 
12 ppm difference between the location of that peak in Form II and Form III. The 13C SSNMR 
spectrum of Form I, the monohydrate, presented in Figure 7.2c has a different set of chemical 
shifts than observed for Forms II and III. The 13C SSNMR spectrum of the degradation product 
of gabapentin, gabapentin lactam is presented in Figure 7.2d. The lactam’s aliphatic region has 
seven peaks; two of these peaks (51 ppm and 38 ppm) are broadened due to coupling with the 
adjacent 14N nucleus. Table 7.1 summarizes the 13C SSNMR chemical shifts of the known 
gabapentin forms as well as gabapentin lactam. A new form of gabapentin was discovered while 
characterizing the known forms; it is presented in the following section.  
7.3.2 New form of gabapentin 
The 13C SSNMR spectrum of spray-dried gabapentin shown in Figure 7.3b (aliphatic 
region only) indicates that it is a mixture of forms. Some of the peaks in the spectrum align with 
Form III, while the other ones do not align with either of the other known forms of gabapentin, 
suggesting that they belong to an unknown form of gabapentin. However, a PXRD pattern of the 
same material (Figure 7.4) indicates that it is a mixture of Form I and another form. Since the 
PXRD peaks of the new form were identical to the ones of Form I, that new polymorph was 
denoted the isomorphous desolvate. That form has never been reported to the best of our 
knowledge.  
The isomorphous desolvate was also generated by in-situ dehydration of the monohydrate 
(Form I) inside the NMR spectrometer. Figure 7.3c shows the aliphatic region of the 13C 
SSNMR spectrum of the material obtained after spinning gabapentin monohydrate in the NMR 
rotor for an extended period of time during the NMR experiment; it is a mixture of Form I (22.8  
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Table 7.1. SSNMR chemical shifts of gabapentin forms and gabapentin lactam. The peaks are 
listed in the order that they appear in the spectra. 
 
 Chemical shifts (ppm) 
Form I 
 
178.5 47.4 44.0 36.4 
 
35.6 29.3 
 
27.4 22.6  
Form II 
 
179.5 47.6 39.1 36.2 35.3 34.5 28.2 22.4 21.6 
Form III 177.4 51.2 
 
41.0 37.6 36.3 33.8 27.0 22.1  
Lactam 
 
179.1 50.9 47.6 39.9 38.8 26.9 23.9 22.0  
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Figure 7.3 Aliphatic region of 13C CP/MAS SSNMR spectra of a. gabapentin Form III; b. 
gabapentin spray-dried; c. the mixture of forms generated in situ; d. gabapentin Form II; e. 
gabapentin Form I 
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Figure 7.4 PXRD patterns of a. gabapentin form I; b. gabapentin spray dried 
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and 27.4 ppm), Form II (21.6 and 36.2 ppm), as well as the isomorphous desolvate. The Form II 
and Form I peaks are significantly smaller than the peaks of the isomorphous desolvate, 
suggesting that these forms are present in a lesser amount.  It is not possible to accurately 
quantitate the amount of each form present in the material because differences in relaxation 
behaviors between the forms have not been accounted for when acquiring the spectrum. The 
peaks belonging to Form I are present because the conversion from Form I to the isomorphous 
desolvate was not complete, while peaks from Form II are present because the isomorphous 
desolvate is a metastable form that rapidly converts to the most thermodynamically stable Form 
II in the course of the NMR experiment. The proposed sequence of conversion is the following: 
Form I àIsomorphous desolvate àForm II. 
The differences in chemical shifts, or peak position, in the 13C SSNMR spectra of the 
previously known forms of gabapentin allowed us to distinguish between them. Also, the 
appearance of new peaks permitted us to identify a new form of gabapentin, the isomorphous 
desolvate, which is not identifiable by PXRD. Another helpful parameter in the identification of 
the forms of gabapentin by SSNMR is their proton spin-lattice relaxation  (1H T1) times. 
7.3.3 1H T1 times of the forms of gabapentin 
The 1H T1 of as-received gabapentin Form II is 134 s. Gabapentin Form III has a 1H T1 
value of 63 s. The 1H T1 of gabapentin Form I is 378s suggesting very low mobility. It is possible 
that a hydrogen bonding network between the water and the gabapentin molecules causes this 
form to have this low a molecular mobility. Water can act as a relaxation sink and cause shorter 
1H T1 times when it is mobile in the structure such as in non-stoichiometric hydrates or channel 
hydrates; however, when water is fixed in the crystal lattice, presumably by hydrogen bonding, 
relaxation times can be longer.  
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7.3.4 Effect of milling and hydroxy propylcellulose (HPC) on gabapentin Form II physical form 
conversion  
Gabapentin Form II was milled for 45 min to determine the influence of milling on the 
physical and chemical stability of the material. It was also mixed with a small amount of 
hydroxypropylcellulose (HPC) and subjected to the same treatment. All the samples were then 
placed under stability conditions for 24h (50 ºC/ 0% RH). Table 7.2 describes the preparation 
method for each sample. 
 Figure 7.5 shows the 13C SSNMR spectra of gabapentin Form II and gabapentin Form II-
HPC mixtures before and after milling. The spectra of as-received gabapentin Form II (Figure 
7.5a), and gabapentin Form II mixed with 6.5% HPC (Figure 7.5b) display the same carbon 
chemical shifts and similar linewidths of approximately 12-14 Hz. This indicates that HPC has 
no effect on the physical form of gabapentin in an unground physical mixture.  This was 
expected since physically mixing materials, without milling, generally does not cause changes in 
physical state of the components of the mixture. The spectra of gabapentin Form II milled alone 
and of gabapentin Form II mixed with 6.5% HPC and milled have eight peaks with chemical 
shifts corresponding to gabapentin Form II. The spectrum in Figure 7.5d contains small peaks at 
37 ppm and 41 ppm. Gabapentin milled alone shows no such peaks. 
Figure 7.6 shows that these small peaks align with two of the peaks of Form III. This 
means that when milled in the presence of HPC (6.5% w/v), a small fraction of gabapentin Form 
II converted to Form III. Figure 7.7 shows the aliphatic region of the 13C SSNMR spectrum of 
the unmilled and milled physical mixtures of gabapentin Form II and HPC and confirms this 
observation. Other groups have also observed gabapentin form conversion in the presence of a  
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Table 7.2 Summary of preparation conditions of gabapentin samples and sample notation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation Conditions Sample 
Gabapentin Form II A 
Gabapentin Form II milled for 45 min B 
Gabapentin Form II milled for 45 min and exposed 
to 50 °C/0% RH for 24 h C 
Gabapentin Form II – HPC (6.5%) mixture D 
Gabapentin Form II – HPC (6.5%) mixture milled 
for 45 min E 
Gabapentin Form II – HPC (6.5%) milled for 45 
min and exposed to 50°C/0% RH for 24 h F 
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Figure 7.5 Aliphatic region of 13C CP/MAS SSNMR spectra of a. gabapentin Form II (Sample 
A); b gabapentin Form II mixed with 6.5% HPC (Sample D); c. gabapentin Form II milled for 45 
min (Sample B); d. gabapentin Form II mixed with 6.5% HPC and milled for 45 min (Sample E). 
The peaks in red correspond to Form III  
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Figure 7.6 Aliphatic region of 13C CP/MAS SSNMR spectra of a. gabapentin Form II mixed 
with 6.5% HPC and milled for 45 min (Sample E); b. gabapentin Form III 
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Figure 7.7 Aliphatic region of 13C CP/MAS SSNMR spectra of a. gabapentin Form II mixed 
with 6.5% HPC (Sample D); b. gabapentin Form II mixed with 6.5% HPC and milled for 45 min 
(Sample E); c. gabapentin Form II mixed with 6.5% HPC, milled for 45 min, and exposed to 
50ºC/0% RH (Sample F) 
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variety of excipients 13. It is possible that the heat generated during milling combined with the 
presence of an excipient possibly acting as a stabilizer of the metastable form generated are 
responsible for these observed polymorphic conversions.  
 
7.3.5 Effect of milling and HPC on lactam formation (chemical stability) and 1H T1 times 
The 1H T1 times of the samples were measured before they were submitted to stability 
conditions. Despite the fact that all the milled and unmilled gabapentin and gabapentin-HPC 
samples are mainly composed of crystalline gabapentin Form II, their 1H T1 values are 
significantly different (Table 7.3). Gabapentin and the gabapentin-HPC mixture (Samples A and 
D) have the same 1H T1 value of ~ 130 s. The 1H T1 of gabapentin milled alone (Sample B) was 
41 s, while that of Form II milled and exposed to 50ºC/0% RH (Sample C) was 61 s. The two 
gabapentin-HPC milled samples (Samples E and F) have significantly lower 1H T1 values than 
any of the other gabapentin samples: 11s and 14s. 
The lactam content in all the milled and unmilled samples described above was measured 
before and after thermal stress (50ºC/ 0% RH/ 24h). Those conditions are different from typical 
stress conditions that use high relative humidity because the presence of water has been shown to 
stabilize gabapentin instead of causing it to be less stable 11. Table 7.3 summarizes the results of 
the stability study. The samples that have been milled, Samples B, C, E and F have generated 
some lactam during the milling process as their initial lactam levels, before stability testing, are 
not zero. For all the samples except pure gabapentin Form II (Sample A), some lactam was 
generated during stability studies. Samples E and F generated approximately the same relative 
amount of lactam during stability (~0.5%). They also generated the largest relative amount of 
lactam of all the samples. Comparing the amounts of lactam generated during stability in 
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Table 7.3 Summary of gabapentin stability study and 1H T1 times. The amount of lactam 
generated during the stability study (Δ lactam) is presented in the last column 
 
 
 
 
 
 
 
 
 
 
 
 
 
Preparation conditions Sample 1H T1 (s) 
Initial lactam 
(%w/w) Δ lactam 
Gabapentin Form II A 134 0.000 0.000 
Gabapentin Form II milled for 45 min B 41 0.048 0.109 
Gabapentin Form II milled for 45 min and exposed 
to 50 °C/0% RH for 24 h C 61 0.098 0.134 
Gabapentin Form II – HPC (6.5%) mixture D 130 0.003 0.011 
Gabapentin Form II – HPC (6.5%) mixture milled 
for 45 min E 11 0.110 0.464 
Gabapentin Form II – HPC (6.5%) milled for 45 
min and exposed to 50°C/0% RH for 24 h F 14 0.453 0.467 
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Samples B and C allows us to assess the effect of milling and thermal stress on the chemical 
stability of gabapentin Form II. Comparing those amounts to the ones generated in Samples E 
and F, that contain HPC, suggests that the presence of HPC has a significant impact on the 
chemical stability of gabapentin as more lactam was generated in the latter samples. Moreover, 
these results indicate that unless the materials were milled, exposure to high temperature and low 
humidity conditions did not cause formation of significant amounts of gabapentin lactam 
(<0.2%). Based on the lactam levels generated in the samples during thermal stress, three 
categories of materials emerge: low, medium and high relative chemical stability. The high 
stability group contained less than 0.01% of lactam. It includes as-received gabapentin Form II 
and gabapentin Form II mixed but not milled with 6.5% HPC. The medium stability group is 
composed of samples that contained between 0.01% and 0.1% of lactam, and includes the milled 
gabapentin Form II samples. Finally the low stability group generated more than 0.4% lactam 
and is made up of the milled Form II –HPC samples. 0.4% is the limit placed by the US 
Pharmacopeia on the amount of gabapentin lactam that can be present in tablets of gabapentin.  
7.4 Discussion 
 The milled gabapentin Form II samples had shorter 1H T1 times and were less 
chemically stable than the unmilled materials (Table 7.3). The magnitudes of the 1H T1 times 
obtained for each sample correlate well with the low, medium, and high chemically stable groups 
defined earlier. The high stability group (Samples A and D) has 1H T1 times of ~130s, the 
medium stability group (Samples B and C) has 1H T1 times of 40-60s while the most unstable 
group has the shortest 1H T1 times observed: 11-14s (Samples E and F). These results suggest 
that a correlation exists between 1H T1 time and chemical stability of the gabapentin samples: 
unless milling caused a decrease of the 1H T1 time of gabapentin by more than an order of 
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magnitude, the material generated was not significantly less chemically stable than the unmilled 
as-received material. 
 The most unstable milled materials with HPC (Samples E and F) also contained small 
amounts of metastable gabapentin Form III, as such it is possible that it is that form that then 
converts to gabapentin lactam during stability studies. It is also possible that the presence of 
amorphous HPC creates regions of higher mobility in the material where chemical reactions can 
take place more readily. 
 The work presented in the earlier chapters of this dissertation indicate that particle size 
and the presence of defects are some of the physical explanation for the decrease in 1H T1 time 
observed when milling a crystalline material; therefore we can speculate that the decrease in 
particle size that occurred as a result of milling, which obviously led to an increase in surface 
area, could potentially be responsible for the decrease in chemical stability of gabapentin by 
providing more molecules on the surface that could undergo the dehydration reaction and 
generate the degradation product gabapentin lactam. However, since materials that were milled 
for the same amount of time, and presumably contain similarly sized particles, presented 
different 1H T1 times, it is safe to assume that another factor might be affecting the chemical 
stability of the material as well; that factor might be the presence of crystal defects that are the 
sites of chemical degradations. These crystal defects would also act as relaxation sinks and 
would explain the decrease in 1H T1 time observed.  
 Zong and coworkers developed a kinetic model based on the presence of nucleating 
sites, or defects, to describe the solid-state chemical degradation of gabapentin 21. Their model 
included a parameter denoted gaba* that represents a crystalline gabapentin that is thought to be 
in a disordered state, yet not amorphous, and is likely to generate the degradation product 
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gabapentin lactam. A collaboration with that group has allowed us to measure the 1H T1 times of 
samples for which the amount of gaba*, abbreviated as G*0, had been measured. A correlation 
between the 1H T1 times and the G*0 term appears to exist. The plot correlating the two 
parameters is presented in Figure 7.8; it shows a linear correlation; however, the significance of 
each of the terms in the equation is not yet known. That plot includes ball-milled gabapentin 
Form II, gabapentin Form II milled and kept at 50ºC /0%RH for 24h, as well as tablets of 
gabapentin Form II. The tablets contain the least amount of gaba* and also had the longest 1H T1 
times. Although more data is most likely needed in order to definitely establish that correlation, 
this result again supports the existence of a correlation between API chemical stability and 
SSNMR 1H T1 times. The mechanistic explanation behind such a correlation would rely on a 
Prout-Tompkins kind of chemical stability model, where crystal defects are considered the sites 
of chemical degradation in solids. These crystal defects are also partially responsible for the 
decrease in 1H T1 times observed when milling a material. 
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Figure 7.8 Plot of the log plot of “reactive gabapentin” as defined in (21) versus 1H T1 time for a 
few powdered samples and tablets of gabapentin Form II 
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7.5 Conclusion 
 We showed that milling gabapentin Form II in the presence of a small amount 
of HPC created a chemically unstable crystalline Form II material. The material with the 
shortest SSNMR 1H T1 times also had the lowest chemical stability. The results presented 
in this chapter reinforce the potential for 1H T1 to be used as a possible tool for correlating 
chemical stability predictor for solid crystalline pharmaceuticals. Combined with the 
results presented in the previous chapters, the results presented here allowed us to 
formulate potential hypotheses of the physical basis for the chemical instability of a 
crystalline API including the decrease in particle size occurred upon milling and possible 
crystal defects created upon milling and other processing. 
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Conclusions and Future Directions 
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8.1 Summary  
 The particle size of solid APIs and the presence of crystal defects impacts important 
pharmaceutical properties such as their dissolution rate and the drug bioavailability, as well as 
their chemical and physical stability. The particle size of solid materials also influences the 
ability to manufacture them. Poor manufacturability can lead to powder segregation and lack of 
dose uniformity in the final drug product. As a result, it is important that it be well characterized. 
A number of particle sizing techniques exist but none allow the size characterization of the API 
in the presence of excipients. Solid-state NMR spectroscopy (SSNMR), because it is selective, 
can be used to characterize solid APIs in a formulation. In this dissertation the correlation 
between the particle size of crystalline APIs and their proton spin-lattice relaxation times (1H T1) 
was investigated using model compounds. Dicumarol and salicylic acid were selected as model 
compounds for this study because of their long 1H T1 times and the fact that when ground they 
maintained the same crystalline form while their 1H T1 times decreased. For substances with 
short 1H T1 times, the investigation and findings presented here have less applicability. 
Crystalline samples of the model compounds containing particles with sizes ranging from 1 um- 
800 um were prepared by sieving, spray-drying, and anti-solvent precipitation. These preparation 
techniques were chosen because, unlike grinding, they do not involve mechanical attrition of the 
material, which is known to result in crystal defects being created (1). These defects are known 
to cause decreases in 1H T1 times therefore their presence would interfere with our investigation 
of the effect of particle size on 1H T1 times. 
The model compounds selection and the preparation and physical state characterization 
of the samples of dicumarol and salicylic acid were presented in chapter 4. In Chapter 5 the size 
of the particles in the samples was characterized using two accepted particle-sizing methods: 
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laser diffraction and scanning electron microscopy, and then correlated with the 1H T1 times of 
the materials. Chapter 5 also presented a model that describes the correlation observed between 
the 1H T1 time of the dicumarol and the salicylic acid materials and their particle size. The model 
was based on the assumption that spin diffusion is the main spin-lattice relaxation mechanism. In 
Chapter 6 we presented how SSNMR relaxation time measurements could be used to 
characterize the polydispersity of crystalline powders, using physical mixtures of dicumarol. We 
extended this study to the investigation of the effect of different compaction forces on the 
homogeneity of formulated tablets of salicylic acid. Different 1H T1 times were obtained for 
salicylic acid at all compaction forces, and heavier compaction forces lead to a larger decrease in 
1H T1 time. Also at certain compaction forces, the relaxation of salicylic acid was best described 
with two 1H T1 times. The 1H T1 time of lactose, one of the main excipients in some of the tablets 
was also found to correlate with the dissolution rate of salicylic acid in the tablets. Finally, in 
Chapter 7 we showed that changes in 1H T1 times of ground crystalline gabapentin Form II were 
correlated with the chemical stability of the material: samples with shorter 1H T1 times were the 
least chemical stable. The physical meaning for the reduction in 1H T1 time observed was 
believed to be both the presence of crystal defects and the decrease in particle size of the 
material.  
8.2 Conclusion 
 The work presented here showed that pharmaceutically relevant bulk properties of 
crystalline solids can be characterized by solid-state NMR. It also increased our understanding of 
the physical meaning of changes in proton-spin lattice relaxation times observed in crystalline 
solids. Finally, it reinforces the potential for SSNMR to be used as a prediction tool for the 
behavior of pharmaceutical solids such as dissolution rate, or chemical stability.  
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8.3 Suggestions for future work 
8.3.1 Improvements to the 1H T1 time-particle size model proposed 
A few studies are briefly discussed that could be performed in order to improve the 
model proposed in Chapter 5 and establish its limitations. 
• Study more particle sizes of model system dicumarol and salicylic acid 
 In the work presented here, we attempted to generate particles that spanned as wide a size 
range as possible and spent considerable amounts of time attempting to prepare particles of 
dicumarol by trial and error using anti-solvent precipitation. One avenue that was not explored is 
the preparation of crystalline particles with sizes ranging from 1-10 µm by precipitation followed 
by recrystallization of the dicumarol. This would be performed by just letting the dicumarol 
suspension prepared by anti-solvent precipitation sit at room temperatures for various amounts of 
time. Varying the length of times allowed for recrystallization could lead to crystals of a variety 
of sizes.  
 
• Establish the validity of the model in other systems 
 In order to determine how applicable the findings presented here are to other molecules, 
other compounds need to be studied. Niflumic acid was once considered for use in this study and 
is one system that could be investigated further. The structure and 13C SSNMR spectra of 
niflumic acid are presented in Figure 8.1. Niflumic acid has only one known polymorph and the 
1H T1 time of as-received niflumic acid is 76 s, which is relatively short, however now that the 
correlation has been proposed it would be fairly straight forward to determine whether niflumic 
acid follows the trend of decreasing 1H T1 times with particle size.  
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Figure 8.1 Structure and 13C SSNMR spectrum of as-received niflumic acid 
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Figure 8.2 shows scanning electron microscope images of as-received niflumic acid and a 
sample prepared by precipitating a solution of niflumic acid in ethanol into an aqueous solution 
of Pluronics F 127. The particles obtained have a rod-like morphology. The effect of this type of 
morphology on the 1H T1 time is not known; however likely due to the different sizes present in 
the samples, two 1H T1 times were detected: 6 s and 36 s. Those values are smaller than the 1H T1 
time of as-received niflumic acid. The DSC thermograms of the as-received and precipitated 
niflumic acid are shown in Figure 8.3. An endotherm due to the melting of niflumic acid is 
present in the thermograms around 205 ºC indicating that the precipitated material is crystalline. 
 
8.3.2 Further explore the implications of the work presented here  
• Study the effect of different excipients on the tablet homogeneity and API dissolution rate 
In chapter 6, we showed that the 1H T1 time of salicylic acid in tablets changed with the 
compaction forces used to prepare the tablets. The number of 1H T1 time values detected was 
also dependent on the compression forces used. The two other major components of the tablets 
were lactose monohydrate and microcrystalline cellulose (MCC) or dicalcium phosphate and 
MCC. Different APIs and excipients could be studied in order to determine if the trend of 
decreasing 1H T1 time with increasing compaction forces holds, as well as investigate further the 
influence of lactose monohydrate on the dissolution rate of the API. Materials are often 
described as hard or soft; a studying using excipients from each of these categories would be 
interesting. It might enable the study of mechanisms such as deformation or fragmentation that 
may occur during tableting. 
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Figure 8.2 SEM micrograph of a.as-received niflumic acid; b-c. precipitated niflumic acid 
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Figure 8.3 DSC thermograms of as-received niflumic acid and precipitated niflumic acid 
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• Investigate further the correlation between 1H T1 time and chemical stability 
In Chapter 7 we showed that the 1H T1 time of ground crystalline gabapentin was correlated 
with the chemical stability of the material, most likely because this stability is dependent on the 
presence of crystal defects that are the sites of chemical degradation reactions. Investigating how 
changes in particle size in gabapentin influenced its chemical stability and its 1H T1 time could 
provide some insights on mechanisms of solid-state chemical degradation. However, the 
challenge with using gabapentin to perform this investigation will lie in finding a method to 
engineer the size of particles without causing polymorphic conversions. Aspirin is another 
compound that could be used to perform that study, although it might be difficult to detect 
changes in its 1H T1 time since it is relatively short compared to gabapentin (60 s). 
8.4 Implications of this work 
 The implications of the work presented here include being able to better characterize 
solid pharmaceutical drug candidates throughout the different manufacturing steps and all the 
way to the final formulated drug product. This could result in better drug products, and 
potentially faster drug development thanks to the potential ability for SSNMR to be used as a 
prediction tool for the behavior or solid pharmaceuticals throughout manufacturing. 
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